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Abstract
Some have proposed that all psychotherapies for depression, as well as for other common mental disorders,
are equally efficacious and that they all work through common processes, especially a relationship with a
therapist. One reason it may be difficult to discern differential efficacy among treatments, as well as how they
exert their effects, is that depression and other disorders are heterogeneous in both presentation and
prognosis. The studies presented in the dissertation aimed to explore how heterogeneity in depression may
moderate treatment effects and process-outcome relations. In study 1, a prognostic index (PI) was developed
and treatment differences along the PI were explored in a sample of patients (N = 622) randomized to
treatment as usual (TAU) or stepped care starting with brief therapy (BT) or with cognitive-behavioral
therapy (CBT). The PI comprised five variables: unemployment status, depression severity, hostility, sleep
problems, and lower positive emotionality, all of which predicted a lower likelihood of recovery. For patients
whose PI indicated a high likelihood of recovery (73% of the sample), recovery rates were similarly high
across the treatments. Among patients whose PI indicated a lower likelihood of recovery, patients in the CBT
condition experienced a substantially higher recovery rate (65%) than patients in TAU (40%) or BT (44%).
In study 2, variability in the predictive relationship between the therapeutic alliance and depressive symptom
change was explored in a sample of patients receiving cognitive therapy (CT) for depression (N = 60). The
alliance predicted outcome in the subgroup of clients with 0–2 prior episodes (r = .52), but not in those with
3 or more prior episodes (r = -.02). In study 3, these findings were replicated in an independent sample of
patients receiving CBT for depression, but they did not extend to patients in a psychodynamic therapy
condition. Taken together, these findings suggest that there may be identifiable subgroups of patients for
whom factors common to all treatments will promote symptom change. By contrast, complementary
subgroups, such as those with poorer prognoses or more recurrent histories of depression, may reveal
differences in the efficacies of treatments and their active mechanisms.
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ABSTRACT 
HETEROGENEITY IN MAJOR DEPRESSION: INFLUENCE ON TREATMENT OUTCOMES 
AND PROCESSES-OUTCOME RELATIONS 
Lorenzo Lorenzo-Luaces 
Robert J. DeRubeis 
Some have proposed that all psychotherapies for depression, as well as for 
other common mental disorders, are equally efficacious and that they all work 
through common processes, especially a relationship with a therapist. One reason it 
may be difficult to discern differential efficacy among treatments, as well as how 
they exert their effects, is that depression and other disorders are heterogeneous in 
both presentation and prognosis. The studies presented in the dissertation aimed to 
explore how heterogeneity in depression may moderate treatment effects and 
process-outcome relations. In study 1, a prognostic index (PI) was developed and 
treatment differences along the PI were explored in a sample of patients (N = 622) 
randomized to treatment as usual (TAU) or stepped care starting with brief therapy 
(BT) or with cognitive-behavioral therapy (CBT). The PI comprised five variables: 
unemployment status, depression severity, hostility, sleep problems, and lower 
positive emotionality, all of which predicted a lower likelihood of recovery. For 
patients whose PI indicated a high likelihood of recovery (73% of the sample), 
recovery rates were similarly high across the treatments. Among patients whose PI 
indicated a lower likelihood of recovery, patients in the CBT condition experienced a 
substantially higher recovery rate (65%) than patients in TAU (40%) or BT (44%). 
In study 2, variability in the predictive relationship between the therapeutic alliance 
and depressive symptom change was explored in a sample of patients receiving 
cognitive therapy (CT) for depression (N = 60). The alliance predicted outcome in 
the subgroup of clients with 0–2 prior episodes (r = .52), but not in those with 3 or 
more prior episodes (r = -.02). In study 3, these findings were replicated in an 
independent sample of patients receiving CBT for depression, but they did not extend 
to patients in a psychodynamic therapy condition. Taken together, these findings 
suggest that there may be identifiable subgroups of patients for whom factors 
common to all treatments will promote symptom change. By contrast, 
complementary subgroups, such as those with poorer prognoses or more recurrent 
histories of depression, may reveal differences in the efficacies of treatments and 
their active mechanisms. 
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CHAPTER 1: A PROGNOSTIC INDEX AS A MODERATOR OF OUTCOMES IN THE 
TREATMENT OF MOOD DISORDERS: COMBINING MULTIPLE VARIABLES TO 
INFORM STEPPED CARE ASSIGNMENT 
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ABSTRACT 
Prognostic indices (PIs) that combine more than one variable to predict subsequent 
depression risk may help guide the selection of treatments that differ in intensity. We 
demonstrate the development of a PI and show its promise in guiding treatment 
decisions between treatment as usual (TAU), stepped care starting with a low 
intensity treatment (brief therapy (BT)), or stepped care starting with a high 
intensity treatment (cognitive-behavioral therapy (CBT)). We utilized data from 
depressed patients (N = 622) who participated in a randomized comparison of TAU, 
BT, and CBT in which no statistically significant differences in the primary measure of 
outcome emerged between the three treatments. We developed a PI by predicting 
depression risk at follow-up across the entire sample using a LASSO-style bootstrap 
ranking variable selection procedure. We then examined between-treatment 
differences in outcome as a function of the PI. Unemployment status, depression 
severity, hostility, sleep problems, and lower positive emotionality at baseline 
predicted a lower likelihood of recovery across treatments. The resulting PI 
incorporating these variables produced a good classification accuracy (c = 0.73). The 
PIs of 73% of the patients indicated a high likelihood of recovery from MDD within 
the 2-year study period. Of these, 81% recovered irrespective of condition. Among 
the 27% of the sample with the lowest PIs, patients in the CBT condition experienced 
a higher recovery rate (65%) than patients in TAU (40%) or BT (44%). Replicable 
PIs may aid treatment selection and help streamline stepped models of care. For 
most individuals who are depressed, the differences between existing treatments for 
depression appears to be negligible. Thus, all else equal, lower intensity treatments 
should be prioritized over more intensive ones. For individuals with a more severe 
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course, greater functional impairment, and a higher vulnerability to depression, more 
intensive interventions should be considered. 
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INTRODUCTION 
There is a wide variety of treatments for depression, and these treatments 
differ in how intense they are in terms of the investment and resources required 
from patients and mental health providers. Despite the availability of these different 
types of interventions, current models for the delivery of mental health care for 
depression are known to be inadequate. At one end of the spectrum, some patients 
receive higher intensity interventions than they require to experience symptom 
relief, for example undergoing antidepressant treatment or long-term psychotherapy 
when they could experience comparable benefit from briefer therapies or lifestyle 
changes (Lorenzo-Luaces, DeRubeis, & Bennett, 2015; Lovell & Richards, 2000). 
Conversely, many patients do not receive the intensity of care that they might 
require to experience symptom relief, for example receiving supportive listening 
when they might benefit more from the combination of antidepressant medications 
and an evidence-based psychotherapy (Kocsis et al., 2008; Lecrubier, 2007). It is 
difficult to match patients to the appropriate level of care they need because there 
are few variables that are known to affect treatment response (van Straten, Hill, 
Richards, & Cuijpers, 2015), and mood disorders are extremely heterogeneous in 
their presentation and prognosis (Lorenzo-Luaces, 2015; Parker, 2005). We describe 
an approach to combining variables into a prognostic index (PI) that can be used 
when selecting between treatments that differ in intensity.  
 It is well appreciated that even when two treatment are equally efficacious 
there may be important subgroups of patients who would respond preferentially to 
one of the treatments over the other (DeRubeis et al., 2014; Kang, Janes, & Huang, 
2014; Kraemer, 2013; Wallace, Frank, & Kraemer, 2013). Even when one treatment 
approach is known to be superior, on average, to another treatment or a control, it is 
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still possible that the efficacy of the stronger treatment is confined to a subset of the 
population and that patients can be matched to the intensity of care most 
appropriate to them (Delgadillo, Moreea, & Lutz, 2016). For example, although on 
average antidepressants are reported to be more efficacious than placebos, their 
superiority over placebos seems to be  limited to patients with more severe 
depression (Barbui, Cipriani, Patel, Ayuso-Mateos, & van Ommeren, 2011; Fournier 
et al., 2010; Khan, Leventhal, Khan, & Brown, 2002; Kirsch et al., 2008). Similar 
findings have been reported for psychotherapy (Driessen, Cuijpers, Hollon, & Dekker, 
2010). Although few would argue that these finding should be interpreted to mean 
that antidepressants and psychotherapy are no more than placebo controls, it 
appears that patients with non-severe depression stand to benefit as much from 
interventions that are less intensive or less expensive than treatments that are more 
intensive.  
Stepped models of care for depression and other health conditions rely on the 
logic that many patients can benefit from less intensive interventions before 
requiring high intensity ones, and there is some empirical support for this 
assumption. In a recent study comparing face to face cognitive-behavioral therapy 
(CBT) to stepped care, there were no differences between the two treatments 
conditions and most patients who recovered in stepped care did so in the less 
intensive phases of treatments (Nordgreen et al., 2016).  Although stepped models 
of care represent an improvement over other traditional models of care, they could 
be substantially streamlined if one knew, a priori, who is likely to respond to a low 
intensity treatment and who is likely to require a stronger or more intensive 
treatment. Given the findings suggesting that the efficacy of antidepressants and 
psychotherapy is limited to patients with more severe depression, a logical 
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recommendation for improving treatment delivery would be to start patients with 
severe depression on a high intensity treatment like CBT or an antidepressant and, 
for patients with mild to moderate depression, to start with a lower intensity 
intervention. Indeed, the NICE Guidelines utilize severity as one of the main 
variables guiding treatment selection (National Institute for Clinical Excellence, 
2004). While this is an evidence-based approach to the care of individuals with 
depression, it has as a notable limitation in that it relies on a single variable.  
Findings from studies comparing psychotherapy, medications, and their 
combination highlights the importance of considering the influence of multiple 
variables when deciding between treatments of different intensities. For example, in 
an individual patient data meta-analysis (IPD), comparing monotherapy with CBT or 
interpersonal psychotherapy (IPT) to the combination of either psychotherapy and an 
antidepressant, Thase et al. (1997) reported that combined therapy was not superior 
to CBT or IPT monotherapy in mild depressions. However, combined treatment 
yielded superior recovery rates (60%) than psychotherapy alone (19%) for patients 
with severe and recurrent depression. Similarly, Hollon et al. (2014) reported that 
the superiority of combined treatment with CBT and medications relative to 
medications alone (72.6% vs. 62.5% overall) was limited to the subset of patients 
with severe and non-chronic recurrent major depression, where the difference was 
81.3% vs. 51.7%.  
It would be hard to argue that combining two active treatments like 
psychotherapy and antidepressants is not likely to yield stronger overall effects than 
just using one of these treatments (Forand, Amsterdam, & DeRubeis, 2015). Indeed, 
the findings of Hollon et al. (2014) and Thase et al. (1997) suggested that, overall, 
there was a small advantage for the presumably stronger treatment approach (i.e., 
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combination therapy) vs. the relatively weaker one (i.e., monotherapy with 
medications or psychotherapy). However, it appears that this small average 
difference was the product of a large difference in one group of patients and a small 
or negligible difference in another group(s). A striking feature of these reports is that 
the proportion of the sample that was expected to show a large advantage of the 
stronger treatment approaches was rather low (32.7% for Thase et al.; 32.3% for 
Hollon et al.). Despite this, the differences that were found between the combined 
treatments versus the monotherapies in the respective studies were larger than what 
is commonly reported in the treatment literature.  An even more striking example of 
the importance of considering more than one variable in examining the efficacy of a 
strong vs. a weak (or no) treatment was provided by Nelson et al. (2013). These 
authors explored moderator of response to placebo vs. antidepressants in a very 
large sample of patients (N = 2283) with late-life depression. Overall, a minimal 
difference between antidepressants and placebos was observed. For patients with 
non-chronic depression, there were actually no differences between the two 
treatments. However, a large differences (d = 0.70) was obtained for patients who 
had chronic and severe depression.  
Despite the fact that these studies are promising in that they suggest that 
severity and an additional variable could be used to guide treatment decisions, there 
is a series of issues associated with combining multiple moderator by treatment 
interactions, as done by Thase et al. (1997), Hollon et al. (2014), and Nelson et al. 
(2013). Individual variables may be weak moderators by themselves but, in 
conjunction with other variables, may be part of an overall stronger moderator 
variable. Illustrating this point, Cloitre, Petkova, Su, and Weiss (2016) explored 
moderators of the efficacy of skills training + exposure vs. exposure + supportive 
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listening vs. skills training+ supportive listening for post-traumatic stress disorder 
(PTSD). In that trial, the skills training + exposure condition was superior to the 
other two conditions overall, especially in regard to assessments that took into 
account the follow-up. Although none of the six moderator variables that were tested 
in interaction with treatment predicted outcomes, a composite variable was a strong 
moderator of outcomes in the comparison of exposure only versus social skills 
training only. A similar approach was recommended by Kraemer (2015) who 
asserted that “if there are multiple [moderators] related to the same underlying 
construct, these … should be combined in order both to increase the reliability of the 
measurement of that construct and to avoid problems associated with 
multicollinearity in combining them.” DeRubeis, Gelfand, German, Fournier and 
Forand (2014) argued for the existence of one such construct when they discussed 
patient response profiles. According to these authors, patients differ in the extent to 
which they can benefit from active psychotherapy processes and strong treatment 
approaches. Subsets of patients who are likely to improve much irrespective of 
interventions, as is characteristic of samples of patients with depression, are unlikely 
to reveal specific intervention effects. 
Another way of framing the question of whether the active benefit of 
treatments is circumscribed or especially pronounced in one patient group is in terms 
of a prognostic index (PI). PIs can be thought of as predictive of patients’ 
symptomatology in a future time frame. This information can be considered absent 
the consideration of what treatment will be provided. For example, patients with less 
severe depression are more likely to recover from their depressive episode than 
patients with more severe depression, irrespective of the treatment they receive. 
However, information from a PI can also be used to determine the intensity level of 
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care a patient should receive. Indices that reflect prognosis are also used in health 
research to determine the intensity or an intervention or whether one is needed at 
all. Summarizing findings from a prevention study in which the benefits were most 
pronounced in a specific subgroup of patients, Garber et al. (2016) stated that 
information “based on purely prognostic indices, allows for more efficient use of 
resources and suggests possible prevention targets so as to increase the power of 
the intervention.” (p. 2) A similar recommendation was made by Delgadillo et al. 
(2016) who used a PI to predict the likelihood of experiencing clinically significant 
improvement in a sample of patients with anxiety and depression from the 
Improving Access to Psychological Therapies (IAPT) programme, which included low-
intensity and high-intensity psychotherapy conditions (see also Saunders, Cape, 
Fearon, & Pilling, 2016). When these authors stratified patients according to 
predicted likelihood of improvement, they found differences in likelihood of 
improvement across both treatments conditions and within each treatment condition. 
Patients with the highest likelihood of improvement were likely to improve in anxiety 
irrespective of high- (59%) vs. low-(56%) intensity treatment. By contrast, an 
advantage of the high intensive interventions vs. low-intensity interventions was 
observed (31% vs. 20%) for patients who had a lower likelihood of improvement. 
In the context of a clinical trial in which there were no differences in outcome 
overall between treatment as usual (TAU), stepped care starting with brief therapy 
(BT) or stepped care starting with CBT (CBT), we hypothesized that prognostic status 
would moderate this effect. Among patients who, based on pre-treatment 
characteristics, are predicted to do well, few if any differences in outcome were 
expected between these treatments. However, we predicted that for patients with a 
poorer prognosis the more intensive CBT should outperform TAU and BT.  
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METHODS 
The aim of the trial from which these data were drawn was to compare TAU to 
each of two stepped care regimens. One of the regimens began with a low intensity 
treatment (i.e., BT) and the other began with a high intensity treatment (i.e., CBT; 
Van Straten, Tiemens, Hakkaart, Nolen, & Donker, 2006). The trial was designed so 
as to mimic conditions found in routine care settings. Patients were sampled from a 
representative subsample of 7 of the 47 regional mental health care centers (MHCs) 
that provide mental health care in the Netherlands.  
Outpatients between the ages of 18 and 65 years (N = 5,219) were screened 
for participation in the trial. Exclusion criteria were: the presence of psychotic or 
manic symptoms, a thought disorder, dependence on hard drugs (patients with 
alcohol abuse or dependence were not excluded), high suicide risk, or poor command 
of the Dutch language. Patients who were not excluded on the basis of these criteria 
were screened for the presence of mood and/or anxiety disorders with the INSTEL 
screen, which is a Dutch modified version of the Goldberg-screen (Goldberg, Bridges, 
Duncan-Jones, & Grayson, 1988; Tiemens, 1999). All remaining patients (i.e., those 
who screened positive for a mood or anxiety diagnosis and did not meet exclusion 
criteria, n = 1,608) were followed up for an at-home interview (baseline assessment) 
by a trained research assistant to determine the presence of mood- and/or anxiety 
disorders, using the composite international diagnostic interview (CIDI; Wittchen, 
Robins, Semler, Cottler, & Organization, 1993). Of these patients, 214 could not be 
reached. Patients in the original trial were eligible if they met the criteria for any of 
the following DSM IV (American Psychiatric Association, 2000) disorders: MDD, 
dysthymia, panic disorder, social anxiety, or generalized anxiety disorder. Of the 
1,394 patients who were reached for interview, 214 did not have a DSM-IV mood or 
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anxiety disorder present, 17 had poor command of the Dutch language, and 396 
refused to participate in the study. Thus, in total, 702 patients consented and 
participated in the parent study. In the present paper we focus on the 622 patients 
who met criteria for MDD.  
 Brief therapy. In the 1980s, brief therapy (BT) was introduced in the 
Netherlands as a remedy for lengthy waiting lists. In this study, BT was provided for 
a total of 5 sessions with a maximum of 2 booster sessions in the six-month period 
following treatment completion. During the first session, a scheme was used to 
assess presenting problems (e.g., main symptom complaints, interpersonal 
functioning, and life areas to be worked on). The aim of BT in this study was to 
create hope by clarifying problems and emphasizing and strengthening the patient’s 
own competence and coping skills. 
Cognitive-behavioral therapy. In this study, CBT consisted of five modules 
spanning 11-15 sessions: a) introduction (one session), b) providing information 
about the aim and the procedure of the treatment and assessing patients’ cognitions 
(three sessions); iii) changing cognitions by challenging them (three sessions); iv) 
changing behavior by performing behavior experiments while challenging cognitions 
(three sessions); v) integrating new behavior in patients’ lives by additional behavior 
experiments (one to five sessions).  
The TAU condition consisted of matched care as it was conducted in the 
Netherlands at the time: an interdisciplinary mental health care team reviewed each 
case and patients were assigned to the treatment that they were expected to benefit 
the most from. Treatments varied by type (e.g., dynamic, supportive), format (e.g., 
group, online), and intensity (i.e., duration). TAU, BT, and CBT were considered as 
first steps in a stepped-care model. Therefore, all patients were allowed to switch 
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treatments, during or after treatment completion, if either the patient or the 
therapist was convinced that the clinical effects were insufficient. In other words: 
although the BT and CBT conditions had a set protocol and number of session 
patients were allowed to ‘step up’ from these treatments or from TAU. Patients who 
met the criteria for severe depression in any of the three treatment conditions were 
allowed to receive antidepressant medication in addition to the psychological 
treatment. Following the baseline assessment, initiation of treatment occurred after a 
naturalistic waiting period (in days: TAU: M = 89, SD = 69; BT: M = 50, SD = 43; 
CBT: M = 83, SD = 58). 
Outcomes and missing data 
Patients were interviewed at baseline and then every 3 months, irrespective 
of the timing of treatment initiation and termination. The baseline and one-year 
assessments, as well as the final follow-up, were conducted via face-to-face 
interviews. The primary outcome for the current analyses was recovery at the final 
follow-up, defined by the absence of MDD status. The final follow-up interview 
occurred at least 18 months after enrollment in the study. The first 59 patients who 
entered the study were followed for 24 months; subsequent enrollees were followed 
for 21 months (n = 105) or 18 months (n = 256). In these analyses we controlled 
for follow-up duration, although there was no indication that the follow-up time by 
itself, or in any of the treatment conditions, was related to recovery status. We also 
examined recovery at the one-year assessment.  
Rates of missing data on baseline co-variates were low (all <10%, see table 
1.1). At the end of the study 68% of the participants (n = 420) were available to be 
interviewed. There were no statistically significant differences in lost-to-follow-up 
(LTFU) between the three treatments (ps > .66). When comparing the 201 
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participants who were LTFU with those who were reached for the final interview, 
depressed patients who were LTFU were more likely to have had a recurrent course 
(62.2% vs. 53.3%, χ2(1) = 4.66, p = .031). To address missing data and LTFU 
issues, we used a non-parametric missing value imputation procedure using random 
forests with the R package missForest (Stekhoven & Bühlmann, 2012). Imputation 
via random forests has the appealing feature of producing a single dataset for 
analysis and has been shown to yield a lower imputation error than the more 
commonly-known approach of multiple imputation via chained equations (MICE; see 
Stekhoven & Bühlmann, 2012; Waljee et al., 2013). To check for the potential that 
missing data imputation influenced our results, we re-ran the analyses described 
below with the listwise-deleted version of the dataset (n = 417). The results were, 
by and large, quite similar so we report the results obtained with the imputed data.  
Analytic approach 
 A total of 23 variables were available for analysis. These variables included 
demographics, clinical variables, personality traits as assessed by the NEO Five 
Factor Inventory (Costa & MacCrae, 1992), and the clinical subscales of the Dutch 
translation of the Symptom Checklist 90 (Derogatis, 1996; Table 1.1). In choosing 
which of these variables we would explore as predictors of treatment outcomes, we 
cross-referenced a recent review by Kessler et al. (2016) on predictors of depression 
treatment outcomes that have been replicated at least once. We also took into 
account multicollinearity, redundancy, and observed variability. Thirteen of the 23 
variables were thus retained (Table 1.1). To determine which of the 13 variables 
would be included in our PI, as well as their weights in the algorithm that would be 
used to predict recovery, we utilized a bootstrap ranking procedure with a 10-fold 
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cross-validated LASSO (least absolute shrinkage and selection operator) penalty in 
1,000 bootstrapped samples (see SparseLearner package; Guo et al., 2015).   
LASSO approaches belong to the family of penalized regression models 
(Tibshirani, 1996, 2011) and have been recommended and used in other efforts to 
predict MDD status (Kessler et al., 2016). They are meant to address the shrinkage 
that is expected to occur when using a model in a sample or population in which it 
was not developed. Variables are standardized, all coefficients are shrunk, and those 
that that are close to zero are set to zero. This is done by specifying a shrinkage 
tuning parameter that sets an upper limit on the sum of the regression coefficients in 
the final LASSO equation. The entirety of the LASSO solutions for all possible values 
of Lambda can be given by a modification of the least angle regression algorithm. In 
this procedure, a first variable is entered into the regression equation based on how 
highly it correlates with the residual from the intercept. The coefficient for that 
variable is increased, starting from zero, in the direction of the correlation until 
another variable is more highly correlated with the residuals and the process 
continues until all variables are in the model. The LARS algorithm can give all 
possible LASSO solutions by setting some variables’ non-zero coefficient to zero. To 
this effect, the LASSO can be used for variable selection (i.e., zero coefficients were 
not selected). In the analyses we conducted with each of the 1,000 bootstrap 
samples, we used 10-fold cross-validation to select, among a range of Lambda 
values, the value that yielded the smallest estimate of the prediction error. This 
procedure converges on a final LASSO solution in which the variables are given the 
set of weights that minimizes prediction error. We refer to this estimate as the 
patient’s value on the PI. Because the PI is derived for a prediction of a binary 
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variable, it is in the form of log odds. To facilitate interpretation, we convert it to an 
estimate of the probability of recovery (PI%).  
We used the traditional interpretation of the c-statistic/area under the curve 
to evaluate the performance of the PI in predicting depression recovery (Austin & 
Steyerberg, 2012). To determine whether outcomes varied between the three 
treatment conditions, we ran binary logistic regressions predicting outcomes at 
follow-up with dummy variables for each of the two active treatment conditions (i.e., 
CBT vs. TAU and BT vs. TAU), the PI, and the respective interactions between the PI 
and treatment condition. We conducted a parallel logistic regression comparing CBT 
vs. BT. In these analyses we controlled for the duration of the follow-up phase (18, 
21, or 24 months) and the number of treatment sessions the patient attended, 
although the inclusion of these covariates did not affect the pattern of results. To 
probe significant interactions, when they occurred, between the PI and treatment 
condition, we used the Johnson-Neyman technique (Hayes & Matthes, 2009). The 
Johnson-Neyman technique is an alternative to the commonly-used method of 
probing interactions between a moderator and a predictor by calculating slopes at 
+/1 standard deviation of the mean of the moderator variable. It gives a value of the 
moderator at which the significance of the predictor on outcome changes. In our 
analyses, the Johnson-Neyman would help us establish a point in the prognostic 
index at which treatment effects begin to be evident. 
RESULTS 
Descriptive statistics are presented in table 1. As would be expected given the 
null results obtained in the full sample in the parent trial, there were no statistically 
significant differences in the rate of MDD recovery between TAU (68.4%) and either 
of the stepped care conditions (BT = 74.9%, OR = 1.30, B = 0.34, SE = 0.23, χ2 = 
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1.33, p = 0.25; CBT = 75.0%, OR = 1.41, B = 0.34, SE = 0.22, χ2 = 2.53, p = 
0.11). Five of the 13 potential predictor variables submitted to the LASSO procedure 
were retained. Being unemployed, having more severe symptoms of depression, 
higher levels of hostility, and having more sleep problems predicted a lower 
likelihood of recovery. Higher levels of extraversion/positive emotionality were 
associated with a higher likelihood of recovery. Table 2.1 shows the standardized 
beta weights assigned to these variables by the LASSO model, along with the results 
obtained when the five variables were entered into a single logistic regression 
predicting likelihood of recovery. The effects of the bootstrapped LASSO procedure 
on the model coefficients can be observed by comparing the LASSO coefficients to 
the respective betas in the logistic regression. For example, the model coefficient for 
unemployment, which was the highest in each of the modeling approaches, shrank 
from -0.62 in the standard regression to -0.48 in the LASSO. By contrast, little 
shrinkage was evident in the coefficient for severity (from -0.18 to -0.16), which was 
the lowest in each of the approaches.  The resulting PI, generated from the LASSO, 
evidenced fair predictive accuracy (c = 0.73, 95% CI = 0.68 – 0.77, p < 0.001).  
The PI was developed by predicting treatment outcomes ignoring the main 
effect of treatment condition on outcomes, which, albeit small and not statistically 
significant, was in the expected direction. Before examining whether the PI was 
related to outcomes across the treatments, we carried out a series of analyses to 
rule out the possibility that there was a systematic influence of treatment condition 
on the PI. First, we evaluated the treatment comparisons in a regression that 
contained the five variables selected previously: unemployment status, depression 
severity, hostility, sleep problems and extraversion. The inclusion of these effects in 
a model containing all the prognostic variables did not affect their statistical 
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significance or the strength of their predictive relation vis a vis outcome. We then 
examined whether the PIs themselves differed between the treatment conditions and 
found no differences (F(2, 618) = 0.95, p = 0.39). Taken together, these results 
suggest that treatment assignment did not influence the PI. 
 In the primary analyses predicting recovery at follow-up, the test of the 
interaction of the PI and the CBT vs. TAU contrast was significant. The direction of 
the effect indicated that, consistent with our hypothesis, the poorer the overall 
prognosis, the greater the advantage of CBT relative to TAU (OR = 1.91, 95% CI: 
1.18 – 3.10, B = 0.65, SE = 0.25 χ2 = 7.00, p = 0.008). The BT/TAU contrast, 
however, did not interact with the PI in the prediction of outcome (OR = 0.94, 95% 
CI: -0.601 – 0.49, B = 0.06, SE = 0.28, χ2 = 0.05, p = 0.83). This pattern was not 
evident in the data from the 1-year assessment (all ps > .35). 
The Johnson-Neyman technique was employed to follow up the significant 
interaction of the PI with the CBT/TAU contrast at follow-up. The result of this 
procedure suggested a cutoff on the PI that reflected a 63% likelihood of recovery, 
and which divided the sample into the 23% with the worst prognoses (i.e., with PI% 
< 60%) and the 77% with better prognoses (i.e., with PI% > 60%). Of the patients 
with better prognoses, 81% recovered and, per Johnson-Neyman, there was no 
difference between the conditions in recovery rates (see Figure 1). By contrast, 
among the patients with poorer prognoses, a significantly higher percentage 
recovered in CBT (65.2%) relative to TAU (39.7%; OR = 2.82, 95% CI: 1.24 – 6.20, 
B = 1.04, SE = 0.40, χ2 = 4.01, p = 0.045). In the BT condition, the recovery rate 
among patients with poor prognoses, 43.5%, was similar to what was observed in 
the TAU condition.  
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To assess whether any single variable unduly influenced the PI, we 
recalculated it five times, each time removing one of the five variables. The results 
remained the same: there was an interaction between the PI and the CBT vs. TAU 
contrast (ORs > 1.69, ps < 0.013). This interaction was not present in the context of 
the BT vs. TAU contrast (ps < 0.60). We also tested the interactions between 
treatment condition and each of the five patient variables separately. None of the 
interaction effects was significant (all ps > 0.09).  
DISCUSSION 
We described a procedure that yields a multi-variable prognostic index that 
can be used in determining which patients are most likely to benefit more from a 
high intensity intervention, relative to a lower intensity one. We tested this 
procedure in the context of a randomized trial of TAU versus BT versus CBT, focusing 
on the patients in the study with a diagnosis of MDD. Despite the trial being 
adequately powered to detect moderate differences and despite the fact that the 
three treatments differed in intensity, across all patients there were only small, 
nonsignificant between-treatment differences in outcomes. Using our prognostic 
index, we identified a subgroup of patients – those with the worst prognoses – for 
whom the effects of CBT were substantially greater than those of TAU or BT. The 
TAU and BT treatment arms in this study were conducted in a naturalistic context in 
which the aim was to treat patients to improvement, even if this required 
augmenting the patient’s original treatment. Thus, it is noteworthy that large 
differences between the interventions were observed in the subset of patients with 
poorer prognoses, according to our index. To put this in context, the difference 
between CBT and TAU that we found (OR = 2.87) is outside the 95% CI of estimates 
of comparisons of CBT vs. TAU reported in the latest meta-analysis exploring long-
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term outcomes between psychotherapies (Karyotaki et al., 2016). This suggests the 
effect we found is not negligible. 
There has been great interest in the use of patient characteristics to match 
patients to the treatments that might be most suitable to them, often in the context 
of treatment options of similar high intensity that are known to be approximately 
equally effective (e.g., CBT, IPT, and antidepressant medications; (DeRubeis et al., 
2014; Huibers et al., 2015; Kang et al., 2014; Kraemer, 2013; Wallace et al., 2013). 
Somewhat less attention has been paid to the use of information about patient 
characteristics to assist in the matching of patients to the level of intensity of care 
that is appropriate to them (Delgadillo, Moreea, & Lutz, 2016). The method we have 
described provides a demonstration of how a statistical method could be used to 
achieve this aim. The first step that is needed is the development of a prognostic 
algorithm estimating the likelihood of being free of MDD at a later point in time. We 
accomplished this by modeling MDD status at follow-up, ignoring treatment 
assignment. This appeared to be reasonable approach in a trial such as this one in 
that there were no statistically significant differences in outcomes between the 
treatments. An analogous example is provided by Huang et al. (2006) in the use of 
breast conservation therapy (BCT). They examined the risk of cancer recurrence as a 
function of patients’ score on a previously-developed prognostic index (Chen et al., 
2005) in BCT, relative to mastectomy plus radiation. Although BCT had previously 
been found to yield a slightly higher risk of recurrence relative to the higher intensity 
mastectomy plus radiation, for patients with good prognoses (a majority of those in 
the sample), there were no differences in recurrence rates between the two 
condition. For patients who were highest on the risk index, rates of relapse were 
substantially higher with BCT group (61%) relative to mastectomy plus radiation 
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(19%). The similarity of this finding with our finding as well as those of Hollon et al. 
(2014), Nelson et al. (2013), and Thase et al. (1997) suggest that across areas of 
health care, prognostic status may serve to moderate the efficacy of higher versus 
lower intensity interventions (see DeRubeis et al., 2014b). For most patients, there 
might be little if any advantage of engaging in the higher intensity treatments. Even 
so, a small and potentially identifiable subgroup of patients could experience 
considerable benefit from higher intensity treatments. 
An alternative approach to developing PIs, as suggested by Kessler et al. 
(2016), is to develop risk models based on variables that are known, from 
naturalistic studies, to predict treatment response. This risk estimate could then be 
tested as a moderator of outcomes in a comparative clinical trial. Kessler et al. argue 
that this approach is more valid than one based, as is the approach we used, on the 
relations derived from a clinical trial. Even if they are correct, one limitation is that 
there might not, in a given context, be convergence on the variables collected in 
epidemiological studies and clinical trials. Moreover, it may be difficult to generalize 
from epidemiological data to populations of patients who meet MDD criteria in clinical 
trial samples, as the latter tend to be more severely impaired, on average (Wiltsey-
Stirman, DeRubeis, Crits-Christoph, & Brody, 2003; Zimmerman et al., 2016).  
Variables that predict differential response to two treatments (i.e., 
prescriptive or moderator variables) are difficult to identify, especially in studies 
underpowered for this purpose, including most published clinical trials. By contrast, 
prognostic variables are easier to identify in that they require less statistical power, 
may be easier to replicate, and may be derived from more naturalistic contexts. The 
variables that were included in our prognostic index, depressive symptom severity, 
unemployment status, sleep complaints, hostility, and extraversion, have been found 
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to predict outcomes in other investigations. Symptom severity (Driessen et al., 
2010; Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008), employment 
status (Delgadillo et al., 2016; Jarrett et al., 2013; Rush, Wisniewski, Warden, & et 
al., 2008; Trivedi et al., 2006), and sleep complaints (Andreescu et al., 2008; Dew 
et al., 1997; Troxel et al., 2011) have been directly implicated as predictors of 
outcome in depression. The various constructs captured by the measures of hostility 
and extraversion – negative affect, low positive emotionality, difficulty in 
interpersonal relationships, and overall maladaptive personality traits— have also 
been reported to predict outcomes across various investigations (see Kessler et al., 
2016). These variables have in common the fact that they capture vulnerability to 
depression, severity, and impairment associated with MDD. Less intensive 
treatments like BT and TAU may not be sufficient to address the vulnerability and 
level of illness severity that patients with a poorer prognosis have. 
 It is widely accepted that all evidence-based psychotherapies for depression 
are equally efficacious (Barth et al., 2013; Cuijpers et al., 2014; Cuijpers, van 
Straten, Andersson, & van Oppen, 2008). However, insofar as comparisons of 
psychotherapies for depression have been conducted with populations that include a 
high proportion of patients who are expected to improve irrespective of treatment 
type, relative differences in the potencies of psychotherapies may have been 
obscured. Providing support for this conjecture, the efficacy of psychotherapy 
relative to controls differs as a function of symptom severity (Driessen et al., 2010). 
Moreover, in several RCTs in which between-treatment differences were not found in 
the full sample, differences were identified in subsamples that comprised the more 
severely depressed patients (Dimidjian et al., 2006; Driessen et al., 2014; Elkin et 
al., 1995; Luty et al., 2007).  
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 Although we found differences between CBT and both BT and TAU, it is worth 
noting that differences emerged in the follow-up phase of the study and were limited 
to a relatively small proportion of the sample. Regarding the first point, it is possible 
that differential effects of psychotherapy are most evident in the long-term (Bell, 
Marcus, & Goodlad, 2013; Bockting, Hollon, Jarrett, Kuyken, & Dobson, 2015; Cloitre 
et al., 2016) in that shorter term outcomes may index remoralization or nonspecific 
effects. Longer term outcomes may reflect whether patients’ underlying vulnerability 
to psychopathology was addressed or whether they acquired tools from therapy to 
deal with their problems (Bell, Marcus, & Goodlad, 2013). Regarding the second 
point, in other instances in which significant differences have been reported in 
subgroups but not in full samples, the subgroups have tended to constitute a 
minority of the sample (Hollon et al., 2014; Nelson et al., 2013). Though it has been 
recognized that most individuals who meet the criteria for MDD show high rates of 
response in any evidence-based treatment, this observation has not been 
incorporated into most guidelines for the treatment of depression. For example, 
Middleton, Shaw, Hull, and Feder (2005) argue that while the UK’s NICE guidelines 
are clear on how to best treat severe depression, there is little guidance available on 
how to treat mild to moderate depression most efficiently. Thus, stepped care 
models that begin with a low-intensity intervention, perhaps an intervention of even 
a lower intensity than the BT implemented in the present study, should be 
investigated further. Exercise, unguided self-help, and internet-based 
psychotherapies all are promising interventions in this regard. Although there is little 
evidence that these interventions are superior to high intensity interventions for 
patients with mild to moderate MDD, they might be preferable in that they achieve 
similar outcomes with lower costs. 
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Table 1.1 Baseline demographic, personality, and clinical characteristics of subjects randomized to treatment as usual (TAU), brief therapy 
(BT), or cognitive-behavioral therapy (CBT) 
 TAU  BT  CBT      
 
% 
 % (n) % (n) % (n) χ
2 p miss. 
Female a 66% (154) 62% (110) 59% (123) 2.17 0.34  
Dutch immigrant a,b 6% (13) 10% (16) 14% (27) 7.51 0.02 10% 
Problematic drinking b 11% (24) 13% (21) 10% (19) 0.69 0.71 9% 
Unemployed|| 36% (77) 30% (48) 31% (57) 2.04 0.36 9% 
Educational attainment||       6.47 0.37 10% 
None 12.6% (26) 9.90% (16) 11.7% (22)    
Lower 39.1% (84) 43.80% (71) 46.3% (87)    
Middle 38.1% (82) 30.20% (49) 30.9% (58)    
High 10.7% (23) 16.00% (26) 11.2% (21)    
Somatic illnesses (#)||       4.12 0.85 8% 
1.00 30.10% (65) 32.70% (53) 30.30% (57)    
2.00 16.70% (36) 20.40% (33) 18.60% (35)    
3.00 9.70% (21) 8.60% (14) 9.60% (18)    
4+ 12.50% (27) 7.40% (12) 8.50% (16)    
Anxiety co-morbidity|| 44.90% (105) 45.80% (82) 48.60% (101) 0.63 0.73  
Severe MDD (CIDI)|| 39.50% (90) 38.20% (66) 41.80% (84) 1.97 0.74 3% 
Recurrent MDD (CIDI)|| 57.70% (135) 49.20% (88) 60.60% (126) 5.43 0.07   
  M SD M SD M SD F p   
Age|| 35.98 (10.29) 36.53 (10.27) 36.63 (9.9) 0.26 0.77  
Symptom Checklist 90          
 
Sleep|| 9.22 (3.85) 9.26 (3.85) 9.29 (3.66) 0.02 0.98 9% 
Agoraphobia a,c 13.29 (6.31) 13.96 (7.03) 14.27 (6.77) 1.13 0.32 9% 
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Anxiety c 26.06 (8.85) 26.18 (8.97) 27.41 (8.77) 1.35 0.26 9% 
Depression c 48.58 (12.35) 47.99 (14.24) 49.15 (12.68) 0.34 0.71 9% 
Hostility|| 12.95 (5.37) 12.49 (5.28) 12.44 (5.36) 0.57 0.57 9% 
Insufficiency a,c 24.93 (7.51) 24.11 (7.95) 25.33 (7.57) 1.14 0.32 9% 
Interpersonal    
     sensitivity c 
42.48 (15.56) 40.87 (15.06) 43.87 (14.96) 1.69 0.19 
9% 
Somaticc 29.51 (9.55) 28.24 (9.52) 28.34 (9.14) 1.12 0.33 9% 
Other a,c 19.32 (5.87) 18.79 (5.92) 19.47 (6.16) 0.61 0.54 9% 
NEO 
         
Conscientiousness a 3.25 (1.95) 2.79 (1.7) 3.11 (1.84) 2.22 0.11 9% 
Agreeableness|| 4.43 (2.06) 4.27 (2.) 4.21 (2.) 0.49 0.62 9% 
Extraversion|| 2.23 (1.83) 3.22 (1.94) 3.12 (1.84) 0.18 0.84 9% 
Neuroticism|| 7.77 (1.13) 1.89 (1.07) 7.88 (1.11) 0.55 0.58 9% 
Openness|| 4.99 (1.87) 4.80 (2.07) 5.39 (1.9) 3.22 0.04 9% 
Note. % miss – percentage missing data at baseline. MDD – major depressive disorder. CIDI - Composite International Diagnostic Interview. 
NEO- NEO Five Factor Inventory. || variable explored as a predictor of outcomes. A – variable not explored as a predictor of outcomes 
because no prior research suggests it is predictive of outcomes in depression treatment, b - variable not explored as a predictor of outcomes 
because there was low variability, c - variable not explored as a predictor of outcomes because it was co-linear  with some variables and 
represented by other variables 
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Table 1.2 LASSO solution for predictor variables used in prognostic index (PI) 
predicting recovery at follow-up and model estimates from logistic regression using 
these variables  
  LASSO B SE OR   
Unemployment status -0.48 -0.62 0.20 0.54 ** 
Depression severity -0.16 -0.18 0.11 0.84 
 
Hostility (SCL) -0.38 -0.45 0.10 0.64 *** 
Sleep complaints (SCL) -0.27 -0.31 0.11 0.73 ** 
Extraversion (NEO)  0.29 0.39 0.11 1.47 *** 
Note: Vertical lines separates results of LASSO solution from results of logistic 
regression. *** p < 0.001, ** p < 0.01, * p <0.05. SCL: Symptom Checklist 90-R 
subscale. NEO: NEO Five Factor Inventory subscale.   
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Figure 1.1 Recovery rates at follow-up between treatment as usual (TAU), and 
stepped care starting with brief therapy (BT) or cognitive-behavioral therapy (CBT) 
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ABSTRACT 
Little is known about the variability of the alliance–outcome correlation across 
identifiable client subsets. This question was explored in a sample of 60 clients 
receiving cognitive therapy for depression, from which an overall correlation of .23 
was observed between alliance ratings and subsequent symptom change. We 
examined interactions between the observer-rated version of the Working Alliance 
Inventory–Short Observer-Rated version (WAI–O; Tracey & Kokotovic, 1989) and 
client demographics, features of depression, personality, and other clinical features 
in predicting subsequent symptom change. After corrections for multiple 
comparisons, interactions between the WAI–O and the number of prior depressive 
episodes, as well as the severity of baseline anxiety symptoms, were significant 
predictors of symptom change. When both interactions were controlled for, number 
of prior depressive episodes emerged as a statistically significant moderator. The 
alliance predicted outcome in the subgroup of clients with 0–2 prior episodes (r = 
.52), but not in those with 3 or more prior episodes (r = .02). These findings were 
obtained despite similar univariate distributions on the alliance and symptom change 
in the 2 subgroups. Differences that were observed in the predictive relation of 
alliance to outcome as a function of number of prior episodes suggest that different 
therapy processes may account for change in these subgroups. If the pattern 
observed in the present study is replicated, it would suggest that the alliance–
outcome association has been both under- and overestimated. 
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INTRODUCTION 
Estimates from meta-analytic reviews indicate a small- to medium-sized 
association between the therapeutic alliance and treatment outcomes (Horvath, Del 
Re, Flückiger, & Symonds, 2011). Although methodological issues in research on the 
alliance have prompted questions about the direction of the causal influence in the 
relation between symptom change and the alliance (e.g., DeRubeis, Brotman, & 
Gibbons, 2005), the alliance remains an important construct in psychotherapy 
research and practice. A relatively unexplored question is to what extent alliance–
outcome associations are moderated by identifiable client characteristics. 
Research on client characteristics and the alliance has, for the most part, 
focused on predictors of the alliance (Castonguay, Constantino, & Holtforth, 2006) or 
on the alliance as a mediator of the relationship between client characteristics and 
outcome (e.g., Shahar, Blatt, Zuroff, & Pilkonis, 2003). Less severe clinical pictures, 
fewer difficulties in interpersonal relationships, and improvement during therapy tend 
to be associated with higher alliance scores. A separate question, which is the focus 
of this report, is whether client characteristics moderate the alliance–outcome 
relationship. Using simulations, DeRubeis, Gelfand, German, Fournier, and Forand 
(2013) have shown that the magnitude of the association between process variables 
and outcome can be heavily influenced by characteristics of the client sample in 
which the correlation is studied. In a meta-analysis that illustrates this point, Sharf, 
Primavera, and Diener (2010) found that the association between the alliance and 
study dropout tends to be smaller in studies that contain higher proportions of clients 
who completed high school. 
Although moderation of the alliance–outcome relationship has been explored 
in other meta-analyses (e.g., Del Re, Flückiger, Horvath, Symonds, & Wampold, 
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2012), a meta-analysis allows one to make inferences about samples, not 
individuals. To our knowledge, only Falkenström, Granström, and Holmqvist (2013) 
have used individual patient data to test client variables as moderators of the 
alliance–outcome relationship. The objective of the present study is to identify client 
characteristics that moderate the alliance–outcome correlation in cognitive therapy 
(CT) for depression. We explored demographic variables, personality traits, and 
other clinical features that have been hypothesized to affect the alliance or its 
relation to outcome. 
Insofar as demographic features, such as gender, age, and marital status, 
influence clients’ perceptions of interpersonal relationships, these may interact with 
the alliance in promoting change (see Flückiger et al., 2013). Personality traits have 
also been explored in relation to the alliance and improvement in psychotherapy. Del 
Re et al. (2012) found that the percentage of clients with personality disorders in 
studies of the alliance was unrelated to the strength of the alliance–outcome 
relationship. However, in a large, heterogeneous sample of mental health clinic 
outpatients, Falkenström et al. (2013) found that the alliance–outcome relationship 
was stronger in clients with personality problems. It has also been suggested that in 
depression, the alliance might be of particular importance with clients with more 
severe, chronic, and recurrent forms (see Arnow et al., 2013). Finally, features that 
reflect the complexity of a client’s clinical picture, including, for example, comorbid 
anxiety (Horvath et al., 2011) or substance use (Flückiger et al., 2013), have been 
considered potential moderators of the alliance–outcome associations. 
METHOD 
Data were drawn from the CT arm (N = 60) of a randomized controlled trial 
comparing CT versus antidepressants in the treatment of moderate to severe major 
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depressive disorder (DeRubeis et al., 2005). The study was approved by the local 
institutional review boards. 
Measures 
Beck Depression Inventory—Second Edition (BDI–II; Beck, Steer, & 
Brown, 1996). Depressive symptoms were assessed with the BDI–II, a 21-item 
self-report measure that was completed by all clients before the start of each 
therapy session as well as at the end of the 16-week treatment period. When a client 
did not provide an end-of-treatment BDI–II, which happened for nine dropouts, we 
used the last available BDI–II score to represent outcome on this instrument. 
Working Alliance Inventory–Short Observer-Rated version (WAI–O; 
Tracey & Kokotovic, 1989). On the WAI–O, observers rate 12 items assessing 
agreement in the goals and tasks of therapy and the affective bond on a 7-point 
scale (from 0 = never to 6 = always; range: 0–72). Ratings used in the present brief 
report constitute a subset of the ratings used by Webb et al. (2011). For each of the 
59 clients who completed at least three sessions of CT, two raters (from a pool of 
five) rated an early session of therapy (Session 3 if available; otherwise Session 2 or 
4). Raters were assigned sessions according to a balanced incomplete block design. 
Pooled ratings for each session yielded estimates of the quality of the alliance. Raters 
received training on the WAI–O and were unaware of the treatment outcomes. They 
achieved adequate reliability (ICC = .73; see Webb et al., 2011, for a more thorough 
description of the procedure). 
Potential moderators 
Demographics. We included age (in years), sex, years of education, marital 
status (married or cohabiting with a partner vs. single), and estimated IQ (derived 
from the Shipley-Harford Living Scale; Shipley, 1940). 
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Personality. We included the five factors of the NEO Five-Factor Inventory. 
Openness, Conscientiousness, Extraversion, Agreeableness, and Neuroticism (Costa 
& McCrae, 1992) and the number of Cluster B and C symptoms individuals endorsed 
in the Structured Clinical Interview for DSM–IV Axis II disorders (Gibbon, Spitzer, & 
First 1997). 
History and features of depression. This set consisted of depression 
severity (Hamilton Rating Scale for Depression; Hamilton, 1960), atypical 
depression, duration of current episode, age at first episode, number of prior 
episodes, and number of prior depression treatments (all assessed by the Structured 
Clinical Interview for DSM–IV–TR Axis I Disorders; First, Spitzer, Gibbon, & Williams, 
2001). 
Other clinical features. We also included number of life events (Psychiatric 
Epidemiology Research Interview Life Events Scale; Dohrenwend, Askenasy, 
Krasnoff, & Dohrenwend, 1978), history of substance abuse (from the Structured 
Clinical Interview for DSM–IV–TR Axis I Disorders interview), severity of anxiety 
symptoms (Hamilton Anxiety Rating Scale; Hamilton, 1959), hopelessness (Beck 
Hopelessness Scale; Beck, Weissman, Lester, & Trexler, 1974) and total score on the 
Attributional Style Questionnaire (ASQ; Peterson et al., 1982). 
Analytic plan 
Continuous variables were centered at their mean. Binary ones were coded 
±0.5. Outliers at three or more standard deviations were winsorized, and nonnormal 
variables were transformed to meet linearity assumptions. The outcome variable was 
residualized subsequent change in depressive symptoms, calculated as the difference 
between the BDI–II score from before the start of the rated session and the end-of-
treatment BDI–II score, controlling for the session BDI–II score. For each of the 23 
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potential moderators, we ran regression models predicting residualized change from 
(a) the WAI–O, (b) the main effect of the potential moderator, and (c) the 
interaction of the potential moderator and the WAI–O. We corrected for multiple 
comparisons with the Benjamini–Hochberg method (Benjamini & Hochberg, 1995), 
using a false discovery rate of p < .05. After this correction, potential moderators 
and their respective interactions with the WAI–O were included together in a 
regression model predicting subsequent change. We used Pothoff’s modification to 
the Johnson–Neyman technique to assess the effect of interactions (Hayes & 
Matthes, 2009). This yields an estimate of the point along the values of the 
moderator at which the predictor–criterion association transitions between 
statistically significant and nonsignificant. 
RESULTS 
Table 2.1 presents descriptive statistics as well as the correlations of all 23 
pretreatment variables with the WAI–O and subsequent change. By itself, the WAI–O 
was related to subsequent symptom change, β = 0.23, χ2(1) = 11.31, p < .001. 
The main effect of none of the 23 variables was significant in the prediction of 
symptom change. However, 4 of the 23 tests of moderation (interaction with the 
alliance) were significant at the p < .05 level (uncorrected). The alliance–outcome 
relationship became stronger with increasing severity of baseline anxiety symptoms, 
β = 0.23, χ2(1) = 14.89, p < .001; increasing levels of self-reported 
conscientiousness, β = 0.22, χ2(1) = 4.60, p = .03; lower scores on measured IQ, β 
= −0.19, χ2(1) = 4.68,p = .03; and fewer prior episodes, β = −0.30, χ2(1) = 
18.45, p < .001. After we corrected for multiple comparisons, only the interactions 
with anxiety severity and number of prior depressive episodes remained significant. 
When a model predicting subsequent change contained the WAI–O, these two 
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moderators, and their interactions, only the interaction between the WAI–O and prior 
episodes remained significant, β = −0.25, χ2(1) = 4.20, p = .04. The interaction 
between the WAI–O and anxiety was reduced to a trend, β = 0.40, χ2(1) = 3.07, p = 
.08. 
The region of significance for predicting outcome with the WAI–O was 
estimated by the Johnson–Neyman technique as all values of prior episodes below 
1.89. Figure 2.1 provides a graphical representation of this association. As depicted 
in Figure 2.2, among clients with zero to two prior episodes of depression, the WAI–
O predicted symptom change, r = .52, 95% confidence interval (CI) [.22, .73], p = 
.001, and its prediction of symptom change was higher than in the group with three 
or more prior episodes, r = −.02, 95% CI [−.41, .38], p = .89. The difference 
between these correlation coefficients was statistically significant (Z = -2.19, p = -
.03). These relationships held for the WAI–O total and were not specific to either of 
its subscales. The means of WAO–I scores were similar for those with zero to two 
versus three or more prior episodes (51.2 vs. 53.6), t(57) = 1.65, p = .10, as were 
the variances (5.23 vs. 5.67), F = 0.95, p = .34. Residualized change in BDI–II score 
was also similar between the groups (11.42 vs. 13.20), t(57) = −0.80, p = .43; 
variances: 8.64 versus 8.40, F = 0.18, p = .67. 
DISCUSSION 
In this sample, the overall alliance–outcome correlation of .23 was well within 
the range of values produced by the latest meta-analysis (Horvath et al., 2011). 
However, the size of this relation varied substantially as a function of the number of 
prior episodes of depression reported at baseline. For clients with fewer than three 
prior depressive episodes, the alliance–outcome correlation was substantially higher 
than what is commonly observed in the literature. In contrast, in the sample of 24 
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patients who had experienced three or more episodes, the alliance was not predictive 
of symptom change. If replicated, this would suggest that by ignoring interactions 
with patient variables, the alliance–outcome correlation can be both over- and 
underestimated. 
Tests of interaction effects require larger sample sizes than tests of main 
effects do. The present study could thus be considered underpowered. In an 
adequately powered study, we may have identified more moderators. The small 
sample also precluded tests of therapist effects or the interaction of therapist and 
client characteristics. Because of the paucity of research on interactions of client 
characteristics and the alliance, we conducted exploratory analyses of multiple 
potential moderators. 
Despite these limitations, the study makes a novel contribution in finding a 
significant interaction between the alliance and an important client variable in 
predicting outcome. That this finding was obtained after correcting for multiple 
comparisons and that it remained significant after controlling for several potential 
confounds suggest it may be robust. The data were well-suited for our research 
question, as they allowed for the control of temporal confounds such as prior 
symptom change, and that the alliance ratings were obtained from observers who 
were unaware of the treatment outcomes as well as most client characteristics. 
Additionally, using observer ratings avoids the potential for the shared variance 
confound that exists when clients’ ratings are used both for the alliance and for the 
outcome variable. It is important to note that the interaction between prior episodes 
and the alliance in the prediction of outcome could not be accounted for by 
differences in the means or variances of the measures of alliance or outcome. Thus, 
it does not appear to be a statistical artifact. 
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Ma and Teasdale (2004) found evidence that patients with three or more prior 
episodes of depression report more childhood adversity, an earlier age of first onset 
of depression, and depressive relapses that more often came out of the blue when 
compared with patients with less recurrent forms of depression. Additionally, it is this 
group with three or more prior episodes of depression that evidences the benefit of 
an intervention to prevent relapse. These findings may be taken to suggest that 
patients who have had zero to two versus three or more prior depressive episodes 
represent essentially different subgroups. Consistent with this research, less 
recurrent forms of depression may be more reactive to negative as well as positive 
life events, whereas more recurrent forms may indicate the presence of ruminative 
and autonomous depressogenic processes. Similarly, Wakefield and Schmitz (2013) 
argued that the recurrence of depressive episodes can be understood as an indicator 
of underlying pathology in the individual, as opposed to reactions to life stressor and 
contextual variables. It is possible that patients with less recurrent depressions tend 
to be more reactive to positive and negative interpersonal interactions, including 
those that are captured in assessments of the therapeutic alliance. For those with 
recurrent depressions, however, the relationship with their therapist, as is true of 
their interpersonal experiences generally, might have little impact on the course of 
their depressive episode, relative to therapy processes that address the intrapsychic 
processes that are known to be especially problematic in this group. 
Although it is widely held that clients are helped differentially by different 
aspects of therapy, few findings in the literature speak to this. The existence of an 
interaction between prior depressive episodes and the alliance in the prediction of 
subsequent symptom change, as well as other interactions between process 
variables and client characteristics (e.g., Strunk, Brotman, DeRubeis, & Hollon, 
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2010), adds empirical support to this clinical intuition. However, these findings also 
present a challenge for psychotherapy research and theories of the mechanisms of 
therapeutic change. Indeed, the existence of substantial moderators of process–
outcome correlations might be responsible for the difficulty in identifying 
mechanisms of change in therapy (DeRubeis et al., 2013). Therapist variables are 
also likely to interact with client characteristics and the alliance to influence outcome. 
Thus, in the interest of achieving a better and more nuanced understanding of 
mechanisms of change in treatment, there is a great need to explore client and 
therapist variables that moderate this and other process–outcome relationships. 
Consistent with recent calls to personalize treatments according to patient 
characteristics (DeRubeis et al., 2014), this type of research would facilitate the 
tailoring of psychological interventions to specific individuals. 
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Table 2.1 Characteristics of the sample and bivariate associations between client 
baseline characteristics, WAI-O ratings and subsequent change 
   WAI-O Symptom 
change 
 M or 
% 
(SD) 
or n 
r r 
WAI-O 52.5 (5.41) -- 0.23*** 
Subsequent Change in BDI 12.2 (8.51) 0.23*** -- 
Demographics 
    
Years of education 14.6 (2.50) -0.10 0.08 
Female % 58% 35 0.02 0.02 
Age 40.3 (11.51) 0.03 0.06 
Married or cohabiting % 30% 18 -0.05 0.17 
IQ 109.7 (10.21) -0.12 0.17 
Personality 
    
NEO - FFI 
    
  Agreeableness (0 – 48) 28.4 (6.38) 0.27 0.12 
  Conscientiousness (0 – 48) 26.6 (8.63) 0.17 0.07 
  Extraversion (0 – 48) 20.7 (6.53) 0.08 0.01 
  Neuroticism (0 – 48) 32.4 (7.56) 0.00 0.05 
  Openness (0 – 48) 28.4 (6.72) -0.06 0.15 
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Number of Cluster B Criteria 2.4 (2.49) -0.08 -0.24 
Number of Cluster C Criteria 4.3 (3.50) -0.11 -0.01 
History of depression 
    
Met atypical depression criteria % 28% 17 0.01 0.00 
Depression severity – HRSD (0–53) 23.9 (3.08) -0.20 -0.14 
Duration of current episodes (mo.) 31.4 (35.23) -0.19 -0.04 
Number of prior episodes 2.3 (2.00) -0.19 0.01 
Prior antidepressant treatments 1.7 (1.81) -0.26 -0.04 
Age of onset of first episode 24.2 (12.95) 0.17 0.09 
Other clinical features 
    
Number of life events – PERI (0 – 102) 6.8 (4.37) 0.14 0.15 
Past history of substance abuse % 28% 17 -0.07 0.14 
Attributional Style - ASQ 0.36 (3.05) -0.23 -0.14 
Anxiety severity – HAM-A (0 – 48) 16.6 (5.93) -0.17 0.09 
Hopelessness – BHS (0 – 20) 11.2 (5.16) 0.18 0.08 
Note. WAI – O – Working Alliance Inventory, Observer ratings, Symptom change – 
residualized change in the BDI, IQ – Intelligent Quotient, HRSD – Hamilton Rating 
Scale for Depression, NEO – FFI – NEO – Five Factor Inventory, PERI – Psychiatric 
Epidemiology Research Interview Life Events Scale, ASQ – Attributional Styles 
Questionnaire (positive – negative), HAM-A – Hamilton Anxiety Rating Scale, BHS – 
Beck Hopelessness Scale. ***p <.001. For dichotomous variables, point-biserial 
correlations with the WAI-O and subsequent change are provided. For continuous 
variables, Pearson product-moment correlations with the WAI-O and subsequent 
change are provided. 
 
 
40 
 
 
Figure 2.1 Predicted association between therapeutic alliance and subsequent 
symptom change across prior depressive episodes. BDI = Beck Depression 
Inventory—Second Edition. 
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Figure 2.2 Observed relationship between early ratings of the therapeutic alliance 
and subsequent change, by prior number of episodes. BDI =Beck Depression 
Inventory—Second Edition. 
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ABSTRACT 
A prior study suggested that, in cognitive-behavioral therapy (CBT), the association 
between the working alliance and depression improvement varies as a function of 
prior history of depression. We sought to replicate these findings in CBT and extend 
them to short-term psychodynamic supportive psychotherapy (SPSP) in a sample of 
patients who were randomized to one of these treatments and were administered the 
Helping Alliance Questionnaire (N = 282). Overall, the alliance was a predictor of 
symptom change (d =0.37, p < .001). In SPSP, the alliance predicted symptom 
change for patients with 0-1 episodes (d = 0.33, p = .003) as well for patients with 2 
or more prior episodes (d = 0.39, p = .008). By contrast, in CBT, the alliance was 
related to symptom change for patients with 0-1 prior episodes (d = 0.79, p < .001) 
but not for those with 2 or more prior episodes (d = 0.06, p = .72). These findings 
suggest a complex interaction between patient features and common vs. specific 
therapy processes. In CBT, the alliance relates to change for patients with less 
recurrent depression whereas other CBT-specific processes may account for change 
for patients with more recurrent depression.  
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INTRODUCTION 
 The therapeutic alliance, broadly understood to capture the bond between a 
patient and a therapist as well as the agreement in the goals and tasks of therapy, is 
widely believed to be a robust predictor of outcomes in psychotherapy. For example, 
reviewing the literature on the alliance, Del Re, Horvath, Flückiger, Symonds, and 
Wampold (2012) asserted that:  
“the alliance and outcome have shown a remarkably robust association … 
across different moderating variables such as measures of the alliance, 
measures of outcomes (primary symptom measure and non-targeted 
measures), rating perspectives, type of treatment (e.g., evidence-based, 
manualized, focused on specific ingredients), and context in which treatment 
was delivered.” (p. 643) 
Indeed, the alliance-outcome correlation has been reported across various 
patient populations and treatments (Horvath, Del Re, Flückiger, & Symonds, 2011). 
However, there have been few primary analyses of the moderation of this 
association, and even fewer analyses that have focused on patient characteristics as 
potential moderators (De Bolle, Johnson, & De Fruyt, 2010; Falkenström, Granström, 
& Holmqvist, 2013; Lorenzo-Luaces, DeRubeis, & Webb, 2014). Thus, whether the 
alliance is an equally important predictor of outcomes for all patients and whether it 
is an equally important predictor of outcomes across psychotherapies are still key 
questions in alliance research (Barber, 2009). Moreover, the answers to these 
questions may not be independent. In other words, it is possible that the effect of 
the alliance on outcome is contingent on the interaction between the type of patient 
undergoing treatment and the type of treatment that is being delivered. In one of 
the few studies examining patient-level moderators of the alliance-outcome 
correlation, Lorenzo-Luaces et al. (2014) reported that the alliance-outcome 
correlation in cognitive therapy (CT) for depression was moderated by the number of 
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prior episodes patients reported at baseline. The aim of this report is to replicate 
these findings and extend them to psychodynamic psychotherapy. 
Depressive recurrence 
Lorenzo-Luaces et al. (2014) reported that for patients with fewer than three 
prior episodes of depression, the alliance-outcome correlation was larger in 
magnitude (r = 0.52) than what is commonly reported in the literature (r = 0.28; 
see Horvath et al., 2011). By contrast, for patients with three or more prior 
depressive episodes, the working alliance did not predict outcome (r = -0.02). 
Drawing on prior work on recurrent depression these authors hypothesized that, for 
patients with a highly recurrent course, depression had become more autonomous, 
likely triggered by internal processes such as rumination or cognitive reactivity (Ma & 
Teasdale, 2004; Monroe & Harkness, 2005; Wakefield & Schmitz, 2013). Individuals 
with more recurrent courses are more likely to report depressive episodes that come 
“out of the blue” (Ma & Teasdale, 2004). By contrast, patients with less recurrent 
courses experience depressive episodes that are more closely linked to life stressors 
(Monroe & Harkness, 2005). For these patients, agreement on the goals and tasks of 
CT, which are often focused on concrete changes in behavior and thinking, may be 
sufficient to engender changes in life circumstances and depressed mood. Adding 
support to this hypothesis, Sasso et al. (2014) found that, in the same sample 
investigated by Lorenzo-Luaces et al., therapists’ use of behavioral homework was 
predictive of symptom change for less recurrent depression. It may be that concrete 
behavioral changes, agreed on with the therapist, are sufficient to produce 
substantial symptom change in less recurrent depression. An alternative account of 
symptom change in less recurrent depression is that these patients may be better 
able to benefit from nonspecific influences such as a positive bond with a caring 
therapist.  
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Patients with a more recurrent course depression may have, or may develop 
during their clinical course, a greater vulnerability to depression that needs to be 
addressed in order for treatment to be efficacious. For these patients, agreement on 
the goals and tasks of CT, which are focused on concrete changes in behavior and 
modification of negative automatic thoughts, may not be sufficient to engender 
symptom change. Adding support to this hypothesis, Sasso et al. (2014) found that, 
in the same sample investigated by Lorenzo-Luaces et al. (2014), therapists’ greater 
use of cognitive methods (vs. behavioral homework) was predictive of symptom 
change for clients with more recurrent courses of depression. Keefe et al. (2016) 
found evidence that the specific use of interventions targeted at identifying, 
assessing, and challenging patients’ core beliefs was specifically efficacious for 
patients with more recurrent depression. Taken together, these findings are 
consistent with the notion that CBT for patients with a more recurrent course of 
depression needs to address underlying vulnerability factors, perhaps pertaining to 
underlying core beliefs or schemas, in order to produce symptom change. This is 
consistent with Ma and Teasdale’s (2004) proposition of “escalating cycles of 
ruminative cognitive–affective processing” (p. 31) in more recurrent depressions. 
Mindfulness-based CT (MBCT) was developed with the intent of interrupting these 
processes and MBCT appears to be particularly superior to treatment as usual only 
among patients with more recurrent forms of depression (Piet & Hougaard, 2011). 
Taken together, findings from these studies suggest that the number of prior 
episodes is a moderator of treatment outcomes as well as of process-outcome 
relationships in cognitive-behavioral therapies (CBTs). Thus, the number of prior 
episodes is an important variable to consider in the context of research on 
treatments for depression. 
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The alliance across psychotherapies 
 Meta-analytic reviews suggest that the magnitude of the alliance-outcome 
correlation does not differ substantially between different therapeutic modalities 
(Horvath et al., 2011). These findings could be taken to support the notion that the 
therapeutic alliance is a common factor contributing to treatment outcomes in 
different psychotherapies. However, these findings are not consistent with the fact 
that schools of therapy emphasize the alliance to different degrees. For example, in 
CBTs a positive therapeutic alliance is generally regarded as a necessary condition 
for the implementation of cognitive-behavioral interventions, which are in turn 
assumed to drive therapeutic change (Beck, 2011). In psychodynamic 
psychotherapies, however, the alliance is more than a prerequisite in that 
interventions often rely on the therapeutic relationship as a model. For example, the 
therapist might focus on the relationship as a new and secure environment in which 
the patient is invited to experience and talk about emotions that had previously been 
avoided. Alternatively, the transference aspects of the relationship may be used to 
improve insight into maladaptive expectations with regards to interpersonal 
relationships (de Jonghe et al., 2013). Therapies might also be expected to differ in 
regard to the role of the alliance because a component of the alliance is agreement 
on task and goals, and therapies differ on their stated goals, as well as on the tasks 
that are used.  
Consistent with the differential roles of the therapeutic alliance, several 
research groups have reported that treatments moderates the strength of the 
association between the alliance and outcome. In a study of patients with chronic 
depression, Arnow et al. (2013) found that the alliance was a significantly stronger 
predictor of outcomes in cognitive behavioral analysis systems of psychotherapy 
(CBASP) than it was in a supportive therapy. The authors hypothesized that the 
difference was accounted for by CBASP’s greater emphasis on tasks and goals, a 
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component of the alliance that may be more strongly related to outcomes than the 
affective bond (see Rector, Zuroff, & Segal, 1999; Webb et al., 2011). Similarly, 
Bedics, Atkins, Harned, and Linenhan (2015) reported that, in dialectical behavioral 
therapy (DBT), the therapeutic alliance was associated with decreases in self-
injurious behavior, whereas this relation was not observed in non-behavioral 
community treatment. Recently, Snippe et al. (2015) reported that the alliance 
predicted symptom change in CBT for depression, but not in MBCT. Taken together, 
these tests of moderation suggest a different role for the alliance across therapy 
modalities (see also Strunk et al., 2010; Zilcha-Mano, Roose, Barber, & Rutherford, 
2015), possibly varying according to how directive or task-oriented therapy is.  
Objectives 
 In a new sample of patients with a major depressive episode (Driessen et al., 
2013), we aimed to replicate the finding of an interaction between number of prior 
episodes and the alliance in CBT (Lorenzo-Luaces et al., 2014a). Moreover, we 
attempt to extended the test of this interaction to psychodynamic therapy. 
Replication attempts are extremely rare in psychology (Makel, Plucker, & Hegarty, 
2012), and the rate of unsuccessful replications has spurred a crisis of confidence in 
the findings derived from psychological studies (Open Science Collaboration, 2015). 
Thus, our findings should make a substantial contribution to the field. The 
exploration of patient characteristics and treatment as moderators of the alliance-
outcome correlation is of special importance for treatment research. If the alliance is 
only a predictor of outcomes in some patients but not in others, this could help 
explain why in some studies the alliance predicts outcomes when accounting for prior 
symptom change (Falkenström, Granström, & Holmqvist, 2014) but in others it does 
not (Hendriksen, Peen, Van, Barber, & Dekker, 2014). Moreover, exploring the 
intersection of patient characteristics, common factors, and specific therapeutic 
factors can inform the personalized delivery of psychotherapeutic interventions 
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(Beutler, Forrester, Gallagher-Thompson, Thompson, & Tomlins, 2012; Beutler & 
Martin, 2001). 
METHODS 
Design. This paper draws upon data from a randomized clinical trial (RCT) 
comparing CBT and short-term psychodynamic supportive psychotherapy (SPSP) for 
patients with depression (N = 341; 164 in CBT and 177 in SPSP). This intervention 
study was registered as ISRCTN31263312 with Current Controlled Trials 
(http://www.controlled-trials.com). The study design and the study protocol were 
approved by the Dutch Union of Medical-Ethic Trial Committees for mental health 
organizations (Driessen et al., 2007).  
Participants. Participants were referred by their general practitioner to one 
of three psychiatric outpatient clinics in Amsterdam, The Netherlands. Inclusion 
criteria were: 1) presence of a major depressive episode according to the MINI-
International Neuropsychiatric Interview – Plus DSM-IV criteria (Sheehan et al., 
1998); 2) Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) scores ≥ 
14; 3) age between 18 and 65 years; 4) written informed consent after description 
of the study. Exclusion criteria and other design features have been described 
elsewhere (Driessen et al., 2007; Driessen et al., 2013). Briefly, participants were 
excluded if they were experiencing psychotic or manic symptoms, severe suicidality, 
problematic substance use in the preceding 6 months, or if they were pregnant or 
unable to attend the study assessments, or if they were using medications that 
might influence mental functions. In this trial, the therapeutic alliance was assessed 
at week 5. By this point, 59 patients had dropped out of the trial, 36 in CBT and 23 
in SPSP (p =0.15, Fisher’s exact test). This report is focused on the remaining 282 
patients (82.6% of the sample; 141 in CBT, 141 in SPSP). 
Interventions. Both therapies consisted of 16 individual sessions in the 
course of 22 weeks and were conducted according to published treatment manuals 
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(de Jonghe, 2005; Molenaar, Don, van den Bout, Sterk, & Dekker, 2009). CBT was 
based on the principles described by Beck (1976) and included behavioral activation 
and cognitive restructuring according to a session-by-session protocol with 
homework assignments. SPSP involved an open patient-therapist dialogue in which 
supportive and insight-facilitating techniques are used (de Jonghe et al., 2013). Its 
core technique is adequate psychoanalytic support. The therapist aims to address the 
emotional background of depression by discussing current relationships, internalized 
past relationships, and interpersonal patterns (de Jonghe et al., 2013). 
Psychotherapists in both conditions were trained psychiatrists or psychologists. 
Therapy sessions were not rated for adherence; manual fidelity was checked by 
means of bi-weekly supervision sessions, chaired by a study supervisor, in which 
audio-taped material was discussed. 
Severely depressed (HRDS>24) patients at baseline, as well as moderately 
depressed patients at baseline who developed severe symptoms during treatment 
(HRDS>24), were offered adjunctive antidepressant medication. Medications were 
administrated by a psychiatrist (not the patient’s therapist) according to a protocol 
starting with extended-release venlafaxine 75 mg/day that could be raised to a 
maximum of 225 mg/day. In cases of intolerance or complete nonresponse, patients 
were switched to either citalopram or nortriptyline. Pharmacotherapy consults 
addressed symptom evaluation, side-effects and adherence. The number of patients 
starting pharmacotherapy at baseline or during psychotherapy did not differ 
significantly between the treatment conditions (see Driessen et al., 2013). 
Measures 
 Depression severity. We used continuous scores on the HRSD, a 17-item 
observer-rated measure of depressive symptoms, as the primary outcome measure. 
The HRSD was assessed at baseline, weeks 5, and 10, and at the end of treatment 
(i.e., week 22). HRSD assessors were trained master-level clinical psychology 
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students, not blind to treatment condition, who assessed the HRSD according to the 
Dutch scoring manual (de Jonghe, 1994). The average intraclass correlation 
coefficient over 46 audiotaped assessments scored by multiple assessors was .97. Of 
the 282 patients who remained in the trial through week 5, 247 (88%) provided an 
HRSD score at week 5.  
 Therapeutic alliance. The alliance was assessed with the Helping Alliance 
Questionnaire (HAq-I; Luborsky, Crits-Christoph, Alexander, Margolis, & Cohen, 
1983), an 11-item self-report questionnaire measuring the perceived helpfulness of 
the therapy as well as the quality of the cooperative or working alliance. Items are 
rated on a 7-point Likert scale, with higher scores indicating a stronger therapeutic 
alliance. Because the items measuring the perceived helpfulness of therapy are 
contaminated by prior symptom change, only items 6 – 10, which tap the 
collaborative aspect of the relationship, were analyzed (hereafter we refer to this as 
the HAq-Ic; de Weert-Van Oene, de Jong, Jörg, & Schrijvers, 1999; Hendriksen et 
al., 2010). Of the patients who remained in the trial by week 5, 197 (70%) 
completed the HAq-Ic. The internal consistency of the subscale was 0.88. 
 Depressive recurrences. History of prior depression was ascertained from 
patient’s self-report as part of an unstructured clinical interview with a master’s level 
clinician. Patients indicated whether they had 0, 1, or 2 or more prior depressive 
episodes. 
Analytic Plan 
 Missing HAQ-Ic and HRSD data were handled using non-parametric 
imputation via random forests with the missForest package in R (Stekhoven & 
Bühlmann, 2012). Covariates used for the imputations were the HAq-Ic and HRSD 
scores, treatment condition, prior episodes, and the other baseline variables 
displayed in Table 3.1. All descriptive and inferential analyses were conducted in IBM 
SPSS v.22. Data were centered according to Kraemer and Blasey’s (2004) 
 
52 
 
recommendations. We used hierarchical linear models (HLMs) to predict change over 
time on the HRSD, the primary study outcome. In all analyses, we controlled for 
early symptom change (baseline to week 5), whether the patients were on 
medications, and the medication by treatment interaction.  
To control for the nesting of data within therapists, a variable representing 
therapists was specified as a random effect. We controlled for early symptom 
change, as opposed to including baseline and week 5 HRSD scores, because adding 
early change to the statistical models increased fit more than did adding baseline and 
week 5 scores. Additionally, controlling for baseline HRSD scores would prohibit 
controlling for medication status because these variables are non-independent (i.e., 
baseline HRSD determined whether patients received medication or not). Controlling 
for baseline severity and week 5 severity instead of early change does not change 
the pattern of results. 
We first estimated the overall effect of the alliance on outcomes by modeling 
change on the HRSD as a function of the alliance and the alliance by time interaction. 
Then, to probe whether the alliance interacted with the number of prior episodes, we 
explored the interaction of time, the alliance, and prior episodes, with all lower-order 
interactions and the statistical controls (i.e., early symptom change, medications, 
medications X treatment, and their interactions with time). We also present the tests 
of the alliance X episode X time interaction according to treatment condition. To 
probe whether the relation of prior episodes and alliance in predicting outcomes 
varied as a function of treatment condition, we analyzed the interaction of alliance X 
prior episodes X treatment X time, with the lower-order interactions and statistical 
controls. We present effect size estimates in accordance with the framework of 
Feingold (2013). 
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RESULTS 
 An HAq-Ic was available for a higher proportion of clients with 2+ prior 
episodes (76%), compared to those with 0-1 prior episodes (64%; p = 0.038, 
Fisher’s exact test [FET]). A higher proportion of HAq-Ics were available for clients in 
the SPSP condition (74%) than for clients in the CBT condition (65%), but this 
difference was not significant (p = 0.12, FET). There was a tendency for clients in 
the medication condition (63%) to be less likely to provide an HAq-Ic, relative to 
those not on medication (74%; p = 0.06, FET). There were no differences between 
participants who provided a HAq-I and those who did not on any of the other 
variables listed in Table 3.1 (all ps > 0.16). 
 On average, clients rated their alliance with their therapist as high (M = 5.24, 
SD = 1.01, where the possible range was 1-7; see Table 3.1). Alliance scores were 
non-significantly higher in CBT condition (M = 5.32, SD = 0.90) relative to the SPSP 
condition (M = 5.15, SD = 1.11; t(280) = 1.37, p = 0.17). Alliance scores were not 
correlated with the number of prior episodes reported (r = 0.004, p = 0.95) and the 
test of the interaction of treatment condition with the number of prior episodes in 
predicting the HAq-Ic scores was not significant (B = 0.06, SE = 0.14, x2 = 0.23, p = 
0.63). These results indicate that, as expected, the levels of alliance did not vary as 
a function of the number of prior episodes, treatment condition, or their interaction.  
 The model predicting change on the HRSD yielded a significant relation of the 
alliance to outcome (B = -1.99, SE = 0.38, t(715.8) = -5.18, p < 0.001; d = 0.37). 
The interaction between prior episodes and the alliance was not significant in the 
SPSP condition (B = 0.20, SE = 0.58, t(367.38) = 0.36, p = 0.72). However, in the 
CBT condition, there was a statistically significant interaction between prior episodes 
and the alliance in predicting outcomes (B = 1.88, SE = 0.66, t(349.50) = 2.83, p = 
0.005). Although the interaction between time, the alliance, prior episodes and 
treatment did not reach statistical significance (p = 0.059), examination of the effect 
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sizes associated with changes in the alliance (see Figure 3.1) shows that the alliance 
was a predictor of outcomes in SPSP for participants with 0 – 1 prior episodes (B = -
2.09, SE = 0.69, t(172.69) = -3.00, p = 0.003, d = 0.33) as well as for those with 
2+ episodes (B = -1.79, SE = 0.66, t(191.66) = -2.70, p = 0.008, d = 0.39). By 
contrast, in CBT the alliance was a strong predictor of outcomes for those with 0 – 1 
prior episodes (B = -4.24, SE = 0.93, t(179.96) = -4.56, p < 0.001, d = 0.79) but 
not for those with 2+ episodes (B = -0.30, SE = 0.86, t(166.33) = -0.36, p = 0.72, 
d = 0.06).  
DISCUSSION 
 We aimed to replicate and extend the findings of Lorenzo-Luaces et al. (2014) 
that, in CBT, the association between the therapeutic alliance and subsequent 
change in depression varied as a function of the number of prior depressive episodes 
clients reported at baseline. The present findings suggest that whereas in 
psychodynamic psychotherapy the therapeutic alliance is a robust predictor of 
outcomes, in CBT the effect of the alliance on outcomes is contingent on a client 
characteristic indexed by the number of previous depressive episodes. This finding 
contributes to the small number of studies on the moderation of process-outcome 
relations by suggesting that process-outcome correlations can vary as a function of 
the interaction of common and specific therapeutic processes and identifiable client 
features (Beutler & Harwood, 2002; Beutler & Martin, 2001; DeRubeis, Gelfand, 
German, Fournier, & Forand, 2013). 
Limitations and strengths  
A number of limitations, some of which are the consequences of analyzing 
data collected in a naturalistic context, must be considered when interpreting the 
findings from the present analyses (see Driessen et al., 2007; 2013) for discussions 
of the limitations of the parent RCT). Some of the most notable limitations of the trial 
from which these data were analyzed were the fact that HRSD raters were not 
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blinded to treatment conditions as well as the fact that treatment adherence was not 
formally addressed. We examined moderation of the alliance-outcome relation only 
in the subset of clients who remained in treatment for at least five weeks. Although 
we imputed missing data for clients who were in treatment at week 5 but did not 
complete an alliance assessment, we chose not to impute data for those who 
dropped out early, as this is a systematic reason for missingness. In this way, the 
generalizability of our results is limited. We note, however, that even considering 
only the clients with complete data, the sample size in this study is larger than more 
than 90% of the studies included in the most recent alliance-outcome meta-analysis 
(Horvath et al., 2011).  
Only week 5 assessments of the alliance were available in this trial. Earlier 
assessments are preferable because they are less likely to be contaminated by 
symptom change. We controlled for prior change statistically, but we cannot rule it 
out as a source of contamination. Moreover, the number of prior episodes in this trial 
was assessed as either zero vs. one vs. two or more. This did not allow us to 
estimate the alliance-outcome correlation for the subset of clients who would have 
reported an even higher number of prior episodes.  
Although the four-way interaction between time, the alliance, prior episodes, 
and the treatment condition did not cross the traditional threshold for statistical 
significance, the interaction between time, the alliance, and prior episodes was 
significant in the CBT condition, in the direction and magnitude reported previously 
(Lorenzo-Luaces et al., 2014). The current report thus is noteworthy, especially 
given the so-called replication crisis in psychology (Open Science Collaboration, 
2015) and the fact that interactions are especially difficult to replicate (Benassi & 
Belli, 1989). It is also important to observe that this replication effort occurred in a 
different cultural context, with different measures of both the alliance and of 
depressive symptoms. This suggests that the original findings were unlikely to have 
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resulted from artifacts of the measures used in that study, but that instead they 
reflect true relations between these constructs.  
The alliance in different therapies 
The therapeutic alliance is not a mechanism within the client that mediates 
symptom change, nor is it a set of therapist behaviors. Thus, an account of symptom 
change that invokes the alliance must also consider the behavior of therapists as well 
as the psychological targets that such behavior is presumed to influence. Change in 
overly negative thinking appears to be a general mechanism of change in 
psychotherapies for depression (Lorenzo-Luaces, German, & DeRubeis, 2015). These 
negative thinking patterns are more rigidly held and more easily activated in 
recurrent depression. It is possible that they need to be addressed directly for 
symptom change to occur (Ma & Teasdale, 2004; Monroe & Harkness, 2005).  
Although the goal of changing negative thinking patterns is common to 
psychodynamic and cognitive therapies, the ways in which such changes are 
targeted differs markedly between the therapies. In CBTs, agreement on the goals 
and tasks of therapy, which involve cognitive and behavioral work aimed at fostering 
cognitive change, has been shown to predict subsequent symptom improvement 
(Rector et al., 1999; Webb et al., 2011). In short-term psychodynamic therapy, the 
development of a secure therapeutic relationship is seen as a vital process thought 
to facilitate the development of insights that reveal maladaptive patterns of 
expectations in the context of interpersonal relationships. Moreover, the client is 
encouraged to experience affect that has been avoided. Given that a core technique 
in SPSP is the provision of support, alliance building is technique and vice versa. 
Thus, the therapeutic alliance ratings may represent somewhat different constructs 
across psychotherapies in that they relate to the different roles that the alliance is 
assigned, and the different ways in which change is promoted. Findings from studies 
in which the alliance is measured either in placebo or pharmacotherapy conditions 
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also supports the view that ratings of the therapeutic alliance may represent 
different constructs across treatments (Barber et al., 2014; Strunk et al., 2010; 
Zilcha-Mano et al., 2015). 
Less recurrent depression. Patients with less recurrent depression may 
have less of a latent vulnerability to depressive episodes (Monroe & Harkness, 2005). 
In these patients, the alliance in CBT and SPSP appears to lead to symptom change. 
Life stressors often trigger depression in these individuals. One possibility is that 
they benefit sufficiently from the provision of non-specific support on part of the 
therapist as a way of remoralizing the patient or helping him or her to overcome 
specific problems. Areán et al. (2015) conjectured that the provision of specific 
psychotherapeutic techniques meant to address psychopathology may not be 
necessary for all patients and that many individuals could experience improvement in 
functioning with the provision of assistance dealing with current life stresses. In 
other words, for some patients it may not so much matter whether therapists 
attempt to foster symptom change by engaging in specific techniques like 
encouraging behavioral change, cognitive change, providing support, or exploring 
interpersonal patterns. Rather, engaging in any of these behaviors as a way of 
helping to resolve interpersonal stressors and countering patients’ depressed mood 
may drive symptom change. For these patients, perhaps it is the agreement between 
them and their therapist in a course of action, irrespective of what is being agreed 
about, that promotes symptom change. It is worth observing that the effects of the 
alliance for those with less recurrent courses of depression appeared stronger in CBT 
than in SPSP. One possibility is that it may more conducive to symptom change for 
patients and therapists to focus on concrete (Keefe et al., 2016), especially 
behavioral (Sasso et al., 2014), changes, possibly because they are easier for both 
the patient and the therapist to carry out. This hypothesis should be explored in 
future work. There already are treatment approaches that rely on behavioral 
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strategies as first steps in the treatment of depression only to be succeeded by other 
therapeutic strategies if the behavioral methods do not produce symptom change 
(Alexopoulos & Areán, 2014). 
More recurrent depression. Individuals with more recurrent courses of 
depression often experience depressive episodes as if they came “out of the blue” 
(Ma & Teasdale, 2004). Evidence suggests that individuals with more recurrent 
depression, as those who are considered at high risk for depression, may actually be 
experiencing depression in response to stressors that are very minor, including even 
so-called “daily hassles” (Monroe & Harkness, 2005; Sher, 2004). These minor 
stressors, in vulnerable individuals, may be enough to trigger the cognitive-affective 
networks associated with self-perpetuating depressed mood. Individuals with a 
recurrent history of depression have long histories of experiencing these shifts in 
mood and may therefore may not experience them as being connected to cognitive 
or meta-cognitive patterns. For these individuals, agreement with their therapists in 
the goals and tasks of CBT did not appear to lead to symptom change. It is 
important to observe that individuals with more recurrent depression did not 
experience worse outcomes in CBT than in SPSP, but rather the outcomes were not 
linked to the level of agreement in the goals of CBT. It is possible that agreement in 
the concrete goals and tasks of therapy, at least as they have been discussed early 
in treatment, (i.e., to promote behavioral change and change on negative automatic 
thoughts) does not promote symptom change. Cognitive work at the deeper level of 
schemas (Keefe et al., 2016) that is meant to address the underlying vulnerability to 
depression may be required to promote symptom change. In other words, it may not 
be the work on automatic thoughts per se, a concrete goal of CBT, that leads to 
symptom change, but rather it is the identification of patterns of maladaptive 
thoughts and their underlying schemas that promote symptom change. Alternatively, 
other processes that were not explicit goals of CBT may also account for symptom 
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change in CBT for recurrent depression. For example, a standard course of CBT may 
increase mindfulness (Manicavasagar, Perich, & Parker, 2011), or it may promote 
affective shifts (Hayes et al., 2007), both of which have been hypothesized to reduce 
vulnerability to depression.  
The finding of this study as well of Lorenzo-Luaces et al. (2014), that 
measures of the therapeutic alliance did not predict outcomes for clients with more 
recurrent depression in CBT, should not be taken to mean that the quality of the 
alliance is unimportant for these clients. High scores on measures of the therapeutic 
alliance are typical in most studies of the alliance (Barber, 2009). It is possible that if 
the lower range of alliance scores were sampled, a relationship of the alliance and 
outcomes would be evident for clients with more recurrent depression in CBT. That 
is, even if other therapeutic elements of CBT are promoting symptom change in 
clients with more recurrent depression, it is possible that these require the presence 
of an at least “good enough” therapeutic alliance. 
The finding of an interaction between prior episodes and the alliance in CBT 
raises the question of why such an interaction would not be found in psychodynamic 
therapy. In psychodynamic therapies, the alliance is hypothesized to be key to 
structural change for all clients. Inasmuch as therapist interventions are performed 
using the therapeutic alliance, the alliance may represent a process of 
psychodynamic therapies that is active across all clients. Our findings can be taken 
to lend credence to this view that the alliance is instrumental in psychodynamic 
therapy. It may be that the SPSP goal to analyze maladaptive depressogenic 
patterns that occur throughout the life course (de Jonghe et al., 2013), which is done 
using the therapeutic alliance, produces symptom change because it reveals the 
cognitive-affective schemas that are activated in the context of depression. 
Alternatively, the exploration of affect, which is a stated goal of SPSP but not of CBT, 
may also promote symptom change (Hayes et al., 2007). 
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Conclusions 
 The current findings suggest that psychodynamic and cognitive-behavioral 
therapists achieve symptom change via different means with different clients, rather 
than through the common pathway suggested by proponents of the common factors 
of psychotherapy. Beutler and colleagues have argued for a move away from 
theories of common vs. specific factors of therapy and towards personalizing 
treatments by applying therapeutic procedures that match clients’ presenting style 
(Beutler et al., 2012; Beutler & Harwood, 2002; Beutler & Martin, 2001). Our results 
suggest that the number of prior depressive episodes clients report before initiating 
treatment is an important variable to consider when tailoring treatments to 
individuals. Within psychodynamic therapies, the alliance, in conjunction with other 
processes engaged in treatment, leads to positive outcomes irrespective of the 
number of prior episodes. By contrast, in CBT, it would appear that the processes 
captured by measures of the therapeutic alliances are only predictive of outcomes for 
clients with less recurrent forms of depression. Other CBT processes, for example, a 
greater focus on cognitive change, may better account for symptom change in clients 
with more recurrent depression.  
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Table 3.1 Baseline characteristics of 282 clients assigned to cognitive-behavioral 
therapy (CBT) or short-term psychodynamic supportive psychotherapy (SPSP) for 
depression  
  M  SD % miss. 
HAq-Ic  5.24 1.18 30 
Baseline HRSD 23.38 5.38 0 
Early HRSD change 3.59 5.85 12 
HRSD week 5 19.79 7.39 12 
HRSD week 10 18.30 8.12 16 
HRSD week 22 15.09 8.74 19 
 % N % miss. 
Female 68 193 0 
Married 25 70 0 
Treatment allocation 
  
0 
        CBT 50 141  
        SPSP 50 141  
Medication 37 105 0 
Prior episodes 
  
0 
        0 - 1 episodes 50 141  
        2+ episodes 50 141  
Duration of depression   4 
< 6 months 26 74  
6-12 months 23 66  
12 – 24 months 14 38  
> 24 months 35 93  
Age   1 
19-29 26 70  
30-39 23 80  
40-49 14 86  
50-64 33 46  
Female 68 193 0 
Married 25 70 0 
Employment status   0 
        Employed 39 111  
        Student 4 10  
        Unemployed or other 57 161  
Educational attainment   1 
        Low 21 59   
        Intermediate 46 130   
        High 32 90   
Note. HAq-Ic- Helping Alliance Questionnaire, Cooperation subscale, Alliance 
subscale. % miss = percentage missing data at baseline. HRSD – Hamilton Rating 
Scale for Depression. Early HRSD change – change from week 1 to week 5. 
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Figure 3.1 Association between the alliance and symptom change by treatments and 
prior episodes  
Note: Prediction of change on the Hamilton Rating Scale for Depression from the 
mean score on items 6-10 on the Helping Alliance Questionnaire HAq-Ic, controlling 
for therapist effects, medication status, and early symptom change. The dashed line 
represents the effect of HAq-Ic on symptom change for the whole sample, controlling 
for early change, treatment condition, medication status, and the interaction of 
treatment condition and medication status. CBT = cognitive behavioral therapy, 
SPSP = short-term psychodynamic supportive psychotherapy 
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CHAPTER 4: GENERAL DISCUSSION 
 The studies presented as a part of the dissertation explored ways in which the 
heterogeneous nature of depression moderates treatment effects and the effects of 
treatment processes on outcomes. Taken together, the findings suggest that the 
efficacy of evidence-based psychotherapies and the effects of specific psychotherapy 
processes are limited to specific, potentially identifiable, subsets of clients. Although 
it might seem obvious that heterogeneity should be considered when interpreting 
treatment effects and psychotherapy process research findings, there is very little 
work that specifically addresses this issue.  
 The first study explored differential treatment outcomes in the context of a 
trial that reported negligible differences between a high-intensity treatment regime 
starting with CBT, a lower-intensity stepped care condition starting with BT, and 
treatment as usual (TAU). A closer examination of the data revealed that the 
treatments were equally efficacious for most of the sample, but that CBT was 
superior to BT and TAU in the subset of clients who were expected to have a poorer 
prognosis. The second study explored the variability of the effects of the working 
alliance, a psychotherapy construct traditionally associated with nonspecific or 
common psychotherapy effects that has been reported to have a moderate and 
consistent relation to outcomes. In a sample of clients receiving CT for depression, 
for clients with less recurrent depression the alliance was a stronger predictor of 
outcomes than is generally reported in the research literature. By contrast, for clients 
with more recurrent depression, the alliance did not predict outcomes. In the third 
study, these findings were replicated in the CBT condition of a randomized controlled 
trial (RCT). However, the findings did not generalize to the short-term psychoanalytic 
supportive psychotherapy (SPSP) condition in the RCT, suggesting that this pattern 
may be specific to CBT. 
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In the study of psychotherapy effectiveness, equivalent outcomes between 
different forms of therapy have often been reported, leading to an assumption of 
equipotency of psychotherapies dubbed the “Dodo bird verdict” (Luborsky, Singer, & 
Luborsky, 1975; Messer & Wampold, 2002; Rosenzweig, 1936). Some have gone so 
far as to argue that TAU psychotherapy and manualized evidence-based treatments 
produce equivalent outcomes (Flückiger, Del Re, Munder, Heer, & Wampold, 2014; 
Spielmans et al., 2013). One account that has been given for why all treatments 
should or would be equally efficacious is the common factors theory of symptom 
change (Laska et al., 2014). The proponents of common factors theory assert that all 
psychotherapeutic interventions delivered with the intent of being efficacious (e.g., 
TAU, CBT) are equally effective because they all include: 
“factors that are necessary and sufficient for change: (a) an emotionally 
charged bond between the therapist and patient, (b) a confiding healing 
setting in which therapy takes place, (c) a therapist who provides a 
psychologically derived and culturally embedded explanation for emotional 
distress, (d) an explanation that is adaptive … and is accepted by the patient, 
and (e) a set of procedures or rituals engaged by the patient and therapist 
that leads the patient to enact something that is positive, helpful, or 
adaptive.” (Laska et al., 2014; p. 469) 
An alternative account to the Dodo and the common factors theory is that, 
although many treatments might be equally effective for many clinical conditions, 
some are better suited for dealing with specific problems (DeRubeis, Brotman, & 
Gibbons, 2005). Evidence has recently accumulated to support this position (Bell, 
Marcus, & Goodlad, 2013; Forman et al., 2012; Marcus, O'Connell, Norris, & 
Sawaqdeh, 2014; Poulsen et al., 2014; Tolin, 2010, 2014). For example, Marcus et 
 
65 
 
al. found CBT to be superior to other treatments for anxiety and eating disorders, but 
not for depression. These authors stated that their findings: 
“are consistent with Chambless’ (2002) suggestion that there may be higher 
levels of treatment equivalence for some disorders such as depression and 
greater treatment differences for disorders like panic disorder. In other words, 
there may be Dodo disorders and non-Dodo disorders. Similarly, Westen, 
Novotny, and Thompson-Brenner (2004) noted that short-term targeted 
treatments may be most effective for treating disorders characterized by 
specific discrete symptoms (e.g., panic disorder), but may be less effective 
for treating “generalized affect states” (p. 655) or more characterological 
conditions such as depression or GAD.” (p. 527) 
The findings from study 1 suggest that –even within “Dodo disorders”— there 
is variability in the extent to which treatment differences will be evident. For clients 
with a favorable prognosis, treatment differences may be small or non-existent. In 
this context, it is not too surprising that treatment researchers are frequently 
disappointed by the size of the effect of interventions. Although meta-analytic 
reviews, even those conducted by researchers who are not proponents of evidence-
based practices (EBPs), have yielded estimates suggesting that EBPs are superior to 
TAU (Flückiger et al., 2014; Spielmans et al., 2013; Stewart & Chambless, 2009; 
Wampold et al., 2011; Weisz, Jensen-Doss, & Hawley, 2006), these findings have 
often been dismissed on the grounds that the differences do not appear to be large. 
To the extent that these studies have been conducted in client samples with a 
favorable prognosis, it is to be expected that differences between active treatments 
and controls, as well as between treatments that might differ in their potency, will be 
small. In depression, most comparisons between treatments have been conducted in 
samples of clients with mild to moderate depression (Barth et al., 2013), precisely 
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the types of clients we would expect to benefit from any intervention (Barbui, 
Cipriani, Patel, Ayuso-Mateos, & van Ommeren, 2011; Bower et al., 2013; Driessen, 
Cuijpers, Hollon, & Dekker, 2010; Fournier et al., 2010; Khan, Leventhal, Khan, & 
Brown, 2002; Kirsch et al., 2008). Subgroup analyses by severity have shown some 
differences between psychotherapies but these findings have been inconsistent 
(Dimidjian et al., 2006; Driessen et al., 2014; Elkin et al., 1995; Luty et al., 2007). 
Moreover, severity is only one variable that indexes prognosis. In one study that 
looked at the interaction of variables, Driessen et al. (2014) reported that CBT was 
slightly more effective than SPSP for clients with severe depression (d = 0.36) 
especially if it was not chronic (d = 0.86) whereas a small advantage for SPSP was 
detected in severe and chronic MDD (d = 0.31). These findings suggest that the 
relationship between expected prognosis and treatment outcomes may be curvilinear 
or otherwise more complex than we have presented. 
The fact that for many clients any treatment will lead to symptom change 
should not be dismissed as a statistical artifact or as a reason to focus only on those 
clients who provide evidence of differences between treatments. An understanding of 
the lack of differences between active treatments and controls or TAU, or between 
treatments, has important implications for the delivery of mental health care. Given 
that for clients with a good prognosis there seem to be few appreciable differences 
between treatments, average treatment outcomes cannot be the consideration taken 
when giving treatment to these clients. Other variables, such as cost or ease of 
dissemination, must be considered. For example, it has been argued that behavioral 
activation (BA) should be considered a first-line treatment for depression given that 
it may engender as much change, on average, as CBT, and it is expected by many to 
be easier to disseminate than CBT. Although there are few published data that speak 
to former assertion, and no data that address the latter conjecture, these questions 
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are currently being explored in the United Kingdom (Rhodes et al., 2014). 
Analogously, Alexopoulos and Arean (2014) have developed and tested a stepped 
therapeutic approach that begins with behavioral activation and only adds other 
components of CBT (e.g., cognitive restructuring, emotion regulation skills) if it is 
deemed that they are needed. Although both of these studies represent notable 
advances in research on psychotherapy, the underlying assumption in these 
approaches is that individual therapist contact is required for therapeutic 
improvement. However, as the findings of chapter 1 and the findings from meta-
analytic reviews (Barbui et al., 2011; Bower et al., 2013; Driessen et al., 2010; 
Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008) suggest, clients with a 
more favorable prognosis may not need high-intensity treatments requiring therapist 
contact.  As has been noted by others (Kazdin & Blase, 2011), self-help, media-
based, and technology-assisted interventions may all contribute to reducing the 
burden of disease in clients with a better prognosis.  
In addition to helping guide treatment selection, parsing out heterogeneity in 
depression and other disorders might be required in order to uncover mechanisms of 
treatment and of pathology. As shown in Chapters 2 and 3, processes that are 
assumed to be part of causal chains in psychotherapy may operate differently across 
client types, and even across the type of psychotherapy that is delivered. For 
individuals with less recurrent depression, a positive working alliance irrespective of 
therapy modality (Chapters 2 and 3), the use of behavioral homework (Sasso et al., 
2015), and clients’ self-reported behavioral changes (Lorenzo-Luaces, German, & 
DeRubeis, 2014) appear to be associated with symptom change. In individuals with 
more recurrent depression, cognitive change (Lorenzo-Luaces, German, & DeRubeis, 
2014) and a positive working alliance in psychodynamic therapy (Chapter 3) are 
associated with symptom change. These findings may be interpreted in light of 
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theories of stress sensitization in depression which posit that prior depressive 
episodes change individuals in ways that leave them at a higher risk of developing 
subsequent depressive episodes (Monroe & Harkness, 2005).  
One way in which depression may render individuals at higher risk for 
subsequent depression is by strengthening cognitive-affective networks associated 
with depressive states (Segal, Williams, Teasdale, & Gemar, 1996). Depression then, 
in individuals with more recurrent trajectories, may result from the activation of 
internal vulnerabilities with little or only minor stress, or even autonomously (Ma & 
Teasdale, 2004; Monroe & Harkness, 2005). If this is so, recovery from depression 
for individuals with more recurrent courses may require addressing the internal 
factors (e.g., cognitive reactivity) that underlie the individual’s vulnerability to 
depression. As suggested by the results of post-hoc analyses of the trial from which 
the data in Chapter 2 were derived, addressing cognitive vulnerabilities may be one 
way of fostering symptom change (Lorenzo-Luaces, German, & DeRubeis, 2015; 
Sasso et al., 2015). In the analyses presented in Chapter 3, psychodynamic therapy 
and CBT achieved similar levels of symptom change among clients with more 
recurrent depression, and in dynamic therapy the alliance was related to symptom 
change.  
In a case description of a course of SPSP, de Jonghe et al. (2013) provided 
information that is suggestive of processes that may account for symptom change in 
recurrent depression with SPSP. In the first few sessions, the therapist provides 
psycho-education and discusses day to day coping with symptoms but refrains from 
giving further advice. Next, explanations for depression are explored and the 
therapist emphasizes the relation of depression to circumstances (“there was a lot to 
do … “But somehow I was not ‘there’ at work; it was as if I was constantly 
somewhere else in my thoughts. I was criticized for that and it upset me a great 
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deal.” [p. 618]). At first glance, emphasizing the relation between events and moods 
might not seem highly applicable to clients with a more recurrent course. However, 
the therapist complements this approach by saying: “Everybody’s life … is highly 
determined by what happens and even more by the way events are perceived” (p. 
618, emphasis added). As the therapy progresses, patterns from troubling and 
depressogenic situations are extracted in a supportive-expressive manner (“The 
therapist values her growing awareness of an interfering pattern or theme in her life 
[“being overlooked”])” (p. 619) This is followed by a shift in focus to internal life and 
it is revealed that “[the client] seldom speaks her mind from fear she might “give the 
wrong answer. ‘I am always afraid they’ll think I am a stupid, fat girl’.” (p. 619). The 
client and the therapist have jointly discovered that “the problem is not out there but 
inside her” (p. 619). The subsequent stages of the treatment involve trying to 
uncover the roots of depressive thinking and recognizing that they might be related 
to early life experiences and hence are not facts that should be acted upon. 
It is thus possible to conceptualize the SPSP treatment of recurrent 
depression as providing a meaningful narrative for depression rather than accepting 
that it has simply arisen out of the blue or with little provocation. It might be that it 
does not so much matter whether the narrative is “accurate” but rather whether the 
client is able to recognize depressive thinking when it is activated and counter it with 
adaptive, opposite, beliefs and behaviors. It is of note that the therapist and the 
client worked slowly and collaboratively through this explanation and it required the 
use of supportive interventions that were not meant to challenge thoughts, especially 
early on. Thus, a positive working relationship in which the client and the therapist 
are able to construct a narrative for depression that involves depressogenic thinking 
might explain symptom change in recurrent depression with SPSP. SPSP also entails 
exploration of affect in the working relationship with the therapist and in that sense 
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may produce cognitive change in a manner similar to what likely occurs in exposure-
based CT treatments (Hayes et al., 2007). 
A CBT approach towards promoting symptom change in recurrent depression 
might have been in some sense more straightforward than the SPSP approach 
described above. It may have begun by focusing on thoughts, somewhat reducing 
the importance of a highly positive working alliance. Providing support for this view, 
a recent dismantling trial suggested that the cognitive psychoeducational part of 
mindfulness-based CT may, on average, account for its efficacy in recurrent 
depression relative to the full MBCT package and to TAU (Williams et al., 2014). Note 
that this is not meant to imply that a positive working alliance is not needed for 
clients with recurrent depression undergoing CBT. That is an empirical question that 
existing trials are ill-equipped to answer because most ratings of the therapeutic 
alliance, whether by clients, therapists, or observers, suggest that good working 
relationships characterize the great majority of client-therapist dyads. The most that 
can be said is that, given the “good enough” levels of the working relationship that 
appear to have been present in nearly all the dyads studies in Chapters 2 and 3, in 
CBT the presence of an even better working relationship with a recurrently depressed 
individual did not appear to be necessary for promoting substantial symptom change. 
Individuals with less recurrent depression typically experience depressive 
episodes that are triggered by life stress. It is possible that for many of these 
individuals the process of change in psychotherapy may be better conceptualized as 
one of remoralization and reengagement with positive and rewarding experiences 
(Connor & Walton, 2011). In a similar vein, in a study that failed to find a significant 
difference between problem-solving therapy (PST) and clinical management (CM) + 
PST in a low-income, medically ill population, Areán et al. (2015) conjectured that 
the resolution of health and psychosocial stressors from CM was enough to drive 
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change in depression and increase self-efficacy and problem-solving skills. It may 
have been the case that many of these clients did not have deficits in problem-
solving skills, the pathology PST targets, but were struggling to adjust to their 
environments. It should be an aim of future research to identify subgroups of clients 
that may better helped by therapeutic techniques that focus more on helping clients 
solve external problems than on helping to alleviate pathology.  
One of the guiding assumptions of the research on common factors of 
psychotherapy, like the therapeutic alliance, is that these factors account for 
symptom change for all clients. At the statistical level, an assumption like this can be 
evaluated by conducting a test of whether process-outcome correlations are 
moderated by client features. Meta-analytic reviews have presented tests of whether 
the strength of the magnitude of process-outcome correlations varies as a function of 
the client samples in which studies are conducted. The results of these studies 
suggest that the alliance-outcome correlation diminishes insofar as the study 
samples contain individuals who are more educated (Sharf, Primavera, & Diener, 
2010), have substance use disorders (Flückiger et al., 2013), or belong to racial and 
ethnic minority groups (Flückiger et al., 2013). Because meta-analyses refer to 
studies, and not to individual clients, more primary tests of moderation like the ones 
conducted in Study 2 and 3 are needed. 
Our findings suggest that the alliance is not a common factor either across 
types of clients or across therapeutic modalities. These findings can be understood if 
we consider that agreement on the goals and tasks of the therapy cannot be a 
common factor because the goals and tasks of therapies differ. However, providing 
explanations for processes of change that incorporate the alliance and therapy-
specific variables can prove very challenging at a conceptual level and will probably 
be difficult to detect statistically. Data-mining enterprises such as the ones 
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conducted in Chapter 1 and 2 may reveal interesting relationships that have not 
been theorized. The important issue will be to attempt to replicate and extend these 
findings as in Chapter 3. 
 The findings of heterogeneity as affecting treatment effects and process-
outcome correlations also have important implications for the classification of 
depression. Insofar as there are cases of MDD that may be better understood as 
demoralization, it may be that those individuals lack the pathologies traditionally 
associated with MDD (e.g., maladaptive negative cognitive biases). As such, these 
individuals may not be helped more by treatments that are meant to target the 
pathologies in MDD (e.g., cognitive therapy) more than they would be helped by 
TAU, brief, or low-intensity interventions. It should be the aim of future work to 
differentiate between individuals who are more in need of active and specific 
treatments vs. lower-intensity interventions and to uncover mechanisms of 
pathology that can be linked to treatment effects. 
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